<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Life (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Life (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">life</journal-id>
<journal-title-group>
<journal-title>Life</journal-title>
</journal-title-group>
<issn pub-type="epub">2075-1729</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32517269</article-id>
<article-id pub-id-type="pmc">7345093</article-id>
<article-id pub-id-type="doi">10.3390/life10060082</article-id>
<article-id pub-id-type="publisher-id">life-10-00082</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>State-of-the-Art: Inflammatory and Metabolic Markers in Mood Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9746-8237</contrib-id>
<name>
<surname>Mucci</surname>
<given-names>Federico</given-names>
</name>
<xref ref-type="aff" rid="af1-life-10-00082">1</xref>
<xref ref-type="aff" rid="af2-life-10-00082">2</xref>
<xref ref-type="corresp" rid="c1-life-10-00082">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marazziti</surname>
<given-names>Donatella</given-names>
</name>
<xref ref-type="aff" rid="af1-life-10-00082">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7905-9755</contrib-id>
<name>
<surname>Della Vecchia</surname>
<given-names>Alessandra</given-names>
</name>
<xref ref-type="aff" rid="af1-life-10-00082">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baroni</surname>
<given-names>Stefano</given-names>
</name>
<xref ref-type="aff" rid="af1-life-10-00082">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morana</surname>
<given-names>Paolo</given-names>
</name>
<xref ref-type="aff" rid="af3-life-10-00082">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carpita</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="af2-life-10-00082">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mangiapane</surname>
<given-names>Paola</given-names>
</name>
<xref ref-type="aff" rid="af3-life-10-00082">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morana</surname>
<given-names>Florinda</given-names>
</name>
<xref ref-type="aff" rid="af3-life-10-00082">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morana</surname>
<given-names>Benedetto</given-names>
</name>
<xref ref-type="aff" rid="af3-life-10-00082">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dell’Osso</surname>
<given-names>Liliana</given-names>
</name>
<xref ref-type="aff" rid="af1-life-10-00082">1</xref>
</contrib>
</contrib-group>
<aff id="af1-life-10-00082"><label>1</label>Dipartimento di Medicina Clinica e Sperimentale, Section of Psychiatry, University of Pisa, 56100 Pisa, Italy; <email>dmarazzi@psico.med.unipi.it</email> (D.M.); <email>alessandradellavecchia@gmail.com</email> (A.D.V.); <email>stefanobaroni1967@gmail.com</email> (S.B.); <email>liliana.dellosso@med.unipi.it</email> (L.D.)</aff>
<aff id="af2-life-10-00082"><label>2</label>Dipartimento di Biotecnologie, Chimica e Farmacia, University of Siena, 53100 Siena, Italy; <email>barbara.carpita1986@gmail.com</email></aff>
<aff id="af3-life-10-00082"><label>3</label>Casa di Cura Morana, 91025 Marsala, Italy; <email>paolomorana@yahoo.com</email> (P.M.); <email>paola.mangiapane@virgilio.it</email> (P.M.); <email>florindamorana@gmail.com</email> (F.M.); <email>benedettomorana@gmail.com</email> (B.M.)</aff>
<author-notes>
<corresp id="c1-life-10-00082"><label>*</label>Correspondence: <email>federico.mucci@med.unipi.it</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>6</month>
<year>2020</year>
</pub-date>
<volume>10</volume>
<issue>6</issue>
<elocation-id>82</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>3</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Mounting evidence highlights the involvement of inflammatory/immune systems and their relationships with neurotransmitters and different metabolic processes in mood disorders. Nevertheless, there is a general agreement that available findings are still inconclusive. Therefore, further investigations are required, aimed at deepening the role of possible alterations of biomarkers in the pathophysiology of mood disorders that might lead to more focused and tailored treatments. The present study is a comprehensive review on these topics that seem to represent intriguing avenues for the development of real innovative therapeutic strategies of mood disorders.</p>
</abstract>
<kwd-group>
<kwd>mood disorders</kwd>
<kwd>neurotransmitters/neuroreceptors</kwd>
<kwd>serotonin</kwd>
<kwd>immune system</kwd>
<kwd>neuro-inflammation</kwd>
<kwd>hypothalamus-pituitary-adrenal axis</kwd>
<kwd>neurotrophins</kwd>
<kwd>uric acid</kwd>
<kwd>oxidative stress</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-life-10-00082" sec-type="intro">
<title>1. Introduction</title>
<p>Mood disorders include different conditions characterized by alterations of mood, psychomotricity, and bio-rhythmicity, provoking great subjective suffering and social and relational impairments [<xref ref-type="bibr" rid="B1-life-10-00082">1</xref>,<xref ref-type="bibr" rid="B2-life-10-00082">2</xref>,<xref ref-type="bibr" rid="B3-life-10-00082">3</xref>,<xref ref-type="bibr" rid="B4-life-10-00082">4</xref>]. Major depressive disorder (MDD) and bipolar disorders (BDs) are the most severe and common forms of mood disorders [<xref ref-type="bibr" rid="B5-life-10-00082">5</xref>]. The first is characterized by depressive episodes, while the most typical BD features are alternating mood shifts, of mania or hypomania, with depressive episodes [<xref ref-type="bibr" rid="B6-life-10-00082">6</xref>,<xref ref-type="bibr" rid="B7-life-10-00082">7</xref>,<xref ref-type="bibr" rid="B8-life-10-00082">8</xref>]. The lifetime prevalence of major depressive disorder is around 7% (about 264 million people), and that of bipolar disorders &gt;1% (about 45 million people) [<xref ref-type="bibr" rid="B7-life-10-00082">7</xref>,<xref ref-type="bibr" rid="B8-life-10-00082">8</xref>,<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>]. As noted by the World Health Organization (WHO), it represents the second main cause of disability in 2020, with a critical burden on the worldwide economy [<xref ref-type="bibr" rid="B10-life-10-00082">10</xref>,<xref ref-type="bibr" rid="B11-life-10-00082">11</xref>]. Several authors have hypothesized that unipolar and bipolar depression may represent distinct nosological entities, possibly related to different biological substrates, and sought to differentiate them from a phenomenological point of view [<xref ref-type="bibr" rid="B12-life-10-00082">12</xref>]. Research on this topic is inconclusive, and a probabilistic and dimensional approach (mood spectrum model) prevails today. Therefore, different authors and clinicians tend to identify MDD as a part of a wider continuum, called “bipolar spectrum”, encompassing depressive and manic symptomatology of different severity levels along a longitudinal course. In several patients, the onset of depression may cause them to end up with mania, or, more frequently, depressive symptoms appear mixed with manic symptoms within the same episode [<xref ref-type="bibr" rid="B12-life-10-00082">12</xref>].</p>
<p>Although mood disorders are one of the most common causes of disability worldwide among psychiatric syndromes [<xref ref-type="bibr" rid="B7-life-10-00082">7</xref>,<xref ref-type="bibr" rid="B10-life-10-00082">10</xref>,<xref ref-type="bibr" rid="B13-life-10-00082">13</xref>], their pathophysiology is still unknown, and their pharmacological management is still at issue, given the evidence that they are chronic conditions, with only 30% of patients achieving complete remission of symptoms. For years, after discovery of the first antidepressants (ADs), the so-called tricyclic ADs, the alteration of monoamine neurotransmission, was considered the most relevant pathophysiological mechanism of MDD [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>]. However, data supporting the monoamine hypotheses are inconclusive as they cannot explain the complex clinical picture [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B13-life-10-00082">13</xref>,<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>], and Ads, developed on their basis, have shown limited effectiveness. Only two-thirds of MDD patients may benefit from these pharmacological treatments; furthermore, part of the responders relapse after initial improvement, even if the drug is continued [<xref ref-type="bibr" rid="B16-life-10-00082">16</xref>].</p>
<p>Subsequent studies carried out on ADs and mood stabilizers showed that prolonged exposure might also trigger the activation cascade of different genes involved in expression and synthesis of different trophic factors [<xref ref-type="bibr" rid="B17-life-10-00082">17</xref>,<xref ref-type="bibr" rid="B18-life-10-00082">18</xref>,<xref ref-type="bibr" rid="B19-life-10-00082">19</xref>]. At the same time, it was demonstrated that the plastic properties of neurons are associated with cell morphology changes, with an increase or decrease in synapses and dendritic spine formation [<xref ref-type="bibr" rid="B20-life-10-00082">20</xref>,<xref ref-type="bibr" rid="B21-life-10-00082">21</xref>,<xref ref-type="bibr" rid="B22-life-10-00082">22</xref>], and that the loss of neuronal trophism leads to a reduction in the environmental stimuli adaptation ability of the brain areas regulating emotions. Taken together, these data have contributed to the definition of the "neurotrophic hypothesis", based on the concept of trophism loss in some brain areas after prolonged stressful periods. Experimental studies on rats subjected to chronic stress showed that neurons of the nucleus accumbens, hippocampus, and prefrontal cortex undergo a reduction in the density of the dendritic spines and of the arborization of the synapses, as well as a loss of volume, which is called "shrinking" [<xref ref-type="bibr" rid="B23-life-10-00082">23</xref>,<xref ref-type="bibr" rid="B24-life-10-00082">24</xref>]. Shrinking, a phenomenon also observed in depressed patients and in subjects who undergo chronic stress, is significantly improved by ADs [<xref ref-type="bibr" rid="B25-life-10-00082">25</xref>]. The neurotrophins most involved in mood disorder pathophysiology are the Brain-Derived Neurotrophic Factor (BDNF) and, to a lesser extent, the Glial-Derived Neurotrophic Factor (GNDF). It has been hypothesized that compounds capable of overcoming the blood–brain barrier, and exerting a modulating function on specific genes involved in trophic and/or immune system factors, might represent an opportunity for the development of potential new and more effective psychotropic compounds in the near future. However, the preliminary data on the current experimental compounds are not encouraging due to their severe side effects [<xref ref-type="bibr" rid="B26-life-10-00082">26</xref>,<xref ref-type="bibr" rid="B27-life-10-00082">27</xref>].</p>
<p>Besides the monoaminergic and neurotrophic hypotheses, other neurobiological models of mood disorders have been developed throughout the decades, from the hypothalamus-pituitary-adrenal (HPA) axis dysfunctions to the inflammatory/immune system alterations, to the structural or functional abnormalities of emotional circuits (i.e., the so-called “limbic cortical model” and the “cortico-striatal model”) [<xref ref-type="bibr" rid="B28-life-10-00082">28</xref>,<xref ref-type="bibr" rid="B29-life-10-00082">29</xref>,<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>]. Growing evidence highlights the main role of inflammation in mood disorders, which seems to correlate with all of the other proposed mechanisms, such as the neurotrophin, neurotransmitters, and the HPA axis [<xref ref-type="bibr" rid="B31-life-10-00082">31</xref>,<xref ref-type="bibr" rid="B32-life-10-00082">32</xref>,<xref ref-type="bibr" rid="B33-life-10-00082">33</xref>]. </p>
<p>The purpose of this article is to review the available literature data on the role of inflammation in the pathophysiology of mood disorders, with a particular attention to its interactions with the immune system and other possibly involved pathological components.</p>
</sec>
<sec id="sec2-life-10-00082" sec-type="methods">
<title>2. Methods</title>
<p>According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<xref ref-type="bibr" rid="B34-life-10-00082">34</xref>], the databases of PubMed, Scopus, Embase, PsycINFO, and Google Scholar were accessed in order to research and collect articles that were published only in the English language. Free text terms and MeSH headings were combined as follows: “(inflammation OR metabolic markers OR cytokines OR immune system) AND (mood disorders OR bipolar disorders OR depression)”. All of the authors agreed to include in the review conference abstracts, posters, and case reports if published in indexed journals. The following inclusion criteria were adopted: preclinical accurate studies carried out with standard/proven techniques and clinical studies carried out in children/adults with reliable diagnosis of mood disorders, according to structured interviews and standardized criteria and reliable assessment of outcome measures. All of the authors equally contributed to identifying potential information specific to this topic among the titles and abstracts of the publications. The first selection excluded 4223 titles because: a) they were duplicates; b) they did not concern the scope of the paper; c) they were not informative enough. The second selection excluded 804 abstracts after being read and reviewed, as the information reported did not fulfill the scope of our paper and/or the presented information did not seem relevant to the discussed topic. Subsequently, 144 more publications were excluded after being completely read and evaluated, as they did not provide enough information and/or result sufficiently in line with our review. Finally, 172 papers were included in the present review (<xref ref-type="fig" rid="life-10-00082-f001">Figure 1</xref>). The search was last updated in December 2019.</p>
</sec>
<sec id="sec3-life-10-00082">
<title>3. Inflammation, Immune System, and Mood Disorders</title>
<p>Inflammation is a non-specific process, triggered by internal and external stressors that represent a defense response of the body, but may also contribute to the onset of different diseases. This definition, widely accepted for most somatic diseases, also finds applicability in neuropsychiatric disorders, particularly in mood disorders [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B32-life-10-00082">32</xref>]. </p>
<p>The role of inflammation in mood disorders has been widely studied, although it is yet unclear. Several authors have proposed that stressful stimuli can contribute to the development of mood disorders through the activation of inflammatory processes, which may interfere with the physiological 5-HT functioning, the neurotrophins, and the HPA axis [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B32-life-10-00082">32</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>,<xref ref-type="bibr" rid="B36-life-10-00082">36</xref>,<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B38-life-10-00082">38</xref>,<xref ref-type="bibr" rid="B39-life-10-00082">39</xref>,<xref ref-type="bibr" rid="B40-life-10-00082">40</xref>,<xref ref-type="bibr" rid="B41-life-10-00082">41</xref>]. According to this view, the alteration of the latter mechanisms would be a consequence rather than an etiologic factor of mood disorders [<xref ref-type="bibr" rid="B42-life-10-00082">42</xref>]. In addition, recent studies highlighted the possible role of proteins defined as "inflammasome" as a molecular bridge between psychological stress and adaptive endogenous responses [<xref ref-type="bibr" rid="B40-life-10-00082">40</xref>]. In 2013, Iwata proposed the “inflammasome hypothesis of depression” [<xref ref-type="bibr" rid="B43-life-10-00082">43</xref>]. The inflammasome is a cytosolic protein complex, usually generated in response to infection, but also to many other exogenous and endogenous factors [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B44-life-10-00082">44</xref>]. Currently, it is known that the inflammasome is directly involved in a pro-inflammatory state, oxidative stress and, perhaps, in the onset of depressive symptoms [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B44-life-10-00082">44</xref>,<xref ref-type="bibr" rid="B45-life-10-00082">45</xref>,<xref ref-type="bibr" rid="B46-life-10-00082">46</xref>].</p>
<p>Furthermore, in the last two decades, increased blood and cerebrospinal fluid (CSF) pro-inflammatory cytokine concentrations, including interleukin-1β (IL-1β), IL-6, interferon-γ (IFN-γ), and tumor necrosis factor alpha (TNF-α) were revealed in MDD and BDs [<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>,<xref ref-type="bibr" rid="B47-life-10-00082">47</xref>,<xref ref-type="bibr" rid="B48-life-10-00082">48</xref>,<xref ref-type="bibr" rid="B49-life-10-00082">49</xref>,<xref ref-type="bibr" rid="B50-life-10-00082">50</xref>,<xref ref-type="bibr" rid="B51-life-10-00082">51</xref>], leading to the cytokines hypothesis of mood disorders [<xref ref-type="bibr" rid="B39-life-10-00082">39</xref>] (<xref ref-type="fig" rid="life-10-00082-f002">Figure 2</xref>).</p>
<p>It may seem surprising that the activity of the immune system might influence social experience, but some studies suggest that such influence can provide a survival advantage. It is possible that inflammation might increase sensitivity to negative social experiences (in order to safeguard wellbeing in the event of a possible threat) [<xref ref-type="bibr" rid="B38-life-10-00082">38</xref>,<xref ref-type="bibr" rid="B52-life-10-00082">52</xref>].</p>
<sec id="sec3dot1-life-10-00082">
<title>3.1. Inflammation in CNS</title>
<p>A mild inflammatory state of the central nervous system (CNS) is considered typical of MDD [<xref ref-type="bibr" rid="B53-life-10-00082">53</xref>], as demonstrated by post-mortem studies on the brains of depressed patients [<xref ref-type="bibr" rid="B54-life-10-00082">54</xref>,<xref ref-type="bibr" rid="B55-life-10-00082">55</xref>]. In particular, several data have associated MDD with microglia and astrocytes activation, together with an increased expression of pro-inflammatory mediators and neurotoxic factors, including superoxide, nitric oxide (NO), and TNF-α [<xref ref-type="bibr" rid="B47-life-10-00082">47</xref>,<xref ref-type="bibr" rid="B48-life-10-00082">48</xref>,<xref ref-type="bibr" rid="B49-life-10-00082">49</xref>,<xref ref-type="bibr" rid="B50-life-10-00082">50</xref>,<xref ref-type="bibr" rid="B51-life-10-00082">51</xref>,<xref ref-type="bibr" rid="B56-life-10-00082">56</xref>,<xref ref-type="bibr" rid="B57-life-10-00082">57</xref>]. Even in neurodegenerative diseases, neuro-inflammation is associated with an excessive activation of microglia, which provokes harmful effects and may lead to neurotoxic processes [<xref ref-type="bibr" rid="B55-life-10-00082">55</xref>]. However, the exact causes of the glia activation are still unknown. It was proposed that immune pathway alteration during critical growth phases might prime microglia, while subsequent triggers may spark a severe and prolonged neuro-inflammation, leading to brain damage [<xref ref-type="bibr" rid="B55-life-10-00082">55</xref>]. Further, it was suggested that systemic inflammation might induce neuro-inflammation through glia activation [<xref ref-type="bibr" rid="B58-life-10-00082">58</xref>,<xref ref-type="bibr" rid="B59-life-10-00082">59</xref>,<xref ref-type="bibr" rid="B60-life-10-00082">60</xref>], since cytokines can pass the blood-brain barrier and stimulate immune and endothelial cells to produce inflammatory mediators [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B32-life-10-00082">32</xref>]. Therefore, brain inflammatory activation by external and internal stressful factors could justify the neurodegenerative processes observed in MDD and BDs, as supported by structural alterations observed in several brain areas of depressed and bipolar patients (i.e., prefrontal cortex, hippocampus, and amygdala) [<xref ref-type="bibr" rid="B58-life-10-00082">58</xref>,<xref ref-type="bibr" rid="B59-life-10-00082">59</xref>,<xref ref-type="bibr" rid="B60-life-10-00082">60</xref>]. </p>
<p>It is known that cytokines long-term exposure can trigger depressive episodes. Many patients undergoing immune-therapy with interferon-α (INF-α) developed depressive clinical pictures, especially considering the sub-threshold syndromes [<xref ref-type="bibr" rid="B61-life-10-00082">61</xref>,<xref ref-type="bibr" rid="B62-life-10-00082">62</xref>,<xref ref-type="bibr" rid="B63-life-10-00082">63</xref>,<xref ref-type="bibr" rid="B64-life-10-00082">64</xref>]. The administration of pro-inflammatory cytokines, such as IFNα or their inducers (specifically endotoxins or anti-typhoid vaccination) may precipitate depressive symptoms in healthy subjects [<xref ref-type="bibr" rid="B65-life-10-00082">65</xref>,<xref ref-type="bibr" rid="B66-life-10-00082">66</xref>,<xref ref-type="bibr" rid="B67-life-10-00082">67</xref>]. Besides depressive moods, subjects exposed to endotoxin also showed feelings of social disconnection, and increased neural activity related to pain and threats in response to negative social experiences [<xref ref-type="bibr" rid="B68-life-10-00082">68</xref>,<xref ref-type="bibr" rid="B69-life-10-00082">69</xref>,<xref ref-type="bibr" rid="B70-life-10-00082">70</xref>]. On the contrary, in depressed subjects suffering from other diseases, such as rheumatoid arthritis, psoriasis, and cancer, blockade of TNF-type cytokines or other inflammatory components (such as cyclo-oxygenase 2) significantly reduced depressive symptoms [<xref ref-type="bibr" rid="B71-life-10-00082">71</xref>,<xref ref-type="bibr" rid="B72-life-10-00082">72</xref>,<xref ref-type="bibr" rid="B73-life-10-00082">73</xref>,<xref ref-type="bibr" rid="B74-life-10-00082">74</xref>]. </p>
</sec>
<sec id="sec3dot2-life-10-00082">
<title>3.2. Peripheral Inflammation and Depression</title>
<p>Studies in animals support these observations, in that the administration of cytokines or cytokine inducers (i.e., lipopolysaccharide, LPS) caused depressive phenotypes [<xref ref-type="bibr" rid="B75-life-10-00082">75</xref>,<xref ref-type="bibr" rid="B76-life-10-00082">76</xref>]. According to some authors, even dysfunctional gut permeability could cause a greater bloodstream translocation of intestinal gram-negative bacteria LPS, with consequent systemic inflammation, as described in cases of prolonged inflammation [<xref ref-type="bibr" rid="B77-life-10-00082">77</xref>,<xref ref-type="bibr" rid="B78-life-10-00082">78</xref>,<xref ref-type="bibr" rid="B79-life-10-00082">79</xref>]. According to this hypothesis, higher serum levels of IgM and IgA against six enterobacteria were revealed in MDD subjects when compared with controls [<xref ref-type="bibr" rid="B77-life-10-00082">77</xref>,<xref ref-type="bibr" rid="B78-life-10-00082">78</xref>,<xref ref-type="bibr" rid="B79-life-10-00082">79</xref>]</p>
<p>As already mentioned, cytokine levels show significant variability in mood disorder patients. The majority of available findings reported elevated levels of pro-inflammatory molecules in subjects affected by mood disorders, including pro-inflammatory cytokines (i.e., IL-4, TNF-α, IL-1β, IL-6), soluble receptors of IL-2 and TNF-α type 1 (sIL-2R and sTNFR1, respectively), and reactive protein C (CRP) [<xref ref-type="bibr" rid="B47-life-10-00082">47</xref>,<xref ref-type="bibr" rid="B48-life-10-00082">48</xref>,<xref ref-type="bibr" rid="B49-life-10-00082">49</xref>,<xref ref-type="bibr" rid="B50-life-10-00082">50</xref>,<xref ref-type="bibr" rid="B51-life-10-00082">51</xref>,<xref ref-type="bibr" rid="B80-life-10-00082">80</xref>], indicating innate immune system dysfunctions. Furthermore, great variability in cytokine profiles was also observed in the different phases of the disease (depression, mania, and euthymia), suggesting variable involvement of inflammatory dysfunctions in different mood states and severity [<xref ref-type="bibr" rid="B50-life-10-00082">50</xref>]. Currently, the strongest evidence is an association between pro-inflammatory cytokines and depressive episodes [<xref ref-type="bibr" rid="B81-life-10-00082">81</xref>]. Many inflammatory biomarkers elevated during depressive episodes, but a careful analysis of the literature showed that IL-1β, IL-6, TNF-α, and CRP are the most reliable biological markers. Serum CRP levels were related to decreased motivation and psychomotor retardation [<xref ref-type="bibr" rid="B82-life-10-00082">82</xref>], as well as to symptoms of anxiety in psychiatric patients [<xref ref-type="bibr" rid="B83-life-10-00082">83</xref>,<xref ref-type="bibr" rid="B84-life-10-00082">84</xref>]. Even some polymorphisms of pro-inflammatory cytokine genes, including IL-1β, TNF, and CRP, appeared to be linked with depression and treatment response [<xref ref-type="bibr" rid="B85-life-10-00082">85</xref>,<xref ref-type="bibr" rid="B86-life-10-00082">86</xref>,<xref ref-type="bibr" rid="B87-life-10-00082">87</xref>,<xref ref-type="bibr" rid="B88-life-10-00082">88</xref>].</p>
<p>Biological markers of inflammation appeared to increase, not only in a subset of depressed patients, but also in people with other neuropsychiatric conditions, such as obsessive–compulsive disorder, anxiety, schizophrenia, and post-traumatic stress disorder (PTSD), putting into question their specificity [<xref ref-type="bibr" rid="B39-life-10-00082">39</xref>,<xref ref-type="bibr" rid="B83-life-10-00082">83</xref>,<xref ref-type="bibr" rid="B89-life-10-00082">89</xref>]. Therefore, it was proposed to verify the impact of inflammation in depression according to specific symptoms described in the research diagnostic criteria (RDCs) of the National Institute of Mental Health. Such symptoms refer to anhedonia, anergy, psychomotor impairment, and increased threat sensitivity with the result of anxiety, excitement, and alarm [<xref ref-type="bibr" rid="B83-life-10-00082">83</xref>]. The presence of inflammation seems to reduce the response to ADs, as observed in a recent study in which almost half of resistant subjects, with failure response to conventional treatments, showed a CRP level &gt;3 mg/L (indicative of elevated inflammatory status) [<xref ref-type="bibr" rid="B90-life-10-00082">90</xref>]. Notably, the patient rates with high CRP levels varied according to the examined subjects, being higher in people with a positive history of depression and treatment resistance, child abuse, or other comorbid medical diseases and metabolic syndromes [<xref ref-type="bibr" rid="B90-life-10-00082">90</xref>]. </p>
<p>Finally, T-cells seem to be able to protect laboratory animals from stress and depression [<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B91-life-10-00082">91</xref>]. By transferring T-cells to chronically stressed animals, an antidepressant phenotype was obtained. This observation was associated with the activity of pro-inflammatory cytokines released by T-cells in the meningeal space, particularly IL-4 [<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B91-life-10-00082">91</xref>]. Indeed, IL-4 was related to the stimulation of astrocytes BDNF production and the shift of microglia immune responses towards a neuroprotective M2 phenotype, together with an increase in hippocampal neurogenesis [<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B91-life-10-00082">91</xref>]. Similar results were reported in mice under acute stress conditions, where the migration of T-cells into the choroid plexus (located in the brain ventricles) resulted in an induction of glucocorticoids to the expression of the intercellular adhesion molecule 1 (ICAM1), with reduced anxiety [<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B91-life-10-00082">91</xref>]. Interestingly, regulatory T (T-reg) cells might also modulate inflammatory pathways and ensuring neuronal support during stress [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B41-life-10-00082">41</xref>] (<xref ref-type="fig" rid="life-10-00082-f003">Figure 3</xref>).</p>
</sec>
</sec>
<sec id="sec4-life-10-00082">
<title>4. Effects of Inflammation on the 5-HT System</title>
<p>According to the monoamine hypothesis, the development of MDD resulted from a reduced, depleted, or dysfunctional monoamine neurotransmission. Different factors can cause an alteration in monoamine activity, such as decreased plasma L-tryptophan (L-TRP) concentrations. The low plasma L-TRP levels revealed in MDD have been related to an increased production of IL-1β, TNF-α, and INF-γ [<xref ref-type="bibr" rid="B13-life-10-00082">13</xref>,<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>], which would promote the degradation pathways of L-TRP.</p>
<p>Indeed, pro-inflammatory cytokines may stimulate inflammatory signaling factors, including the nuclear factor (NF)-κB, p38 mitogen-activated protein kinase (MAP-K), and signal transducer and activator of transcription (STAT). One of the different consequences provoked by these transcription factors is the activation of L-TRP catabolism through the enzyme indoleamine 2,3 dioxygenase (IDO) pathway (the so-called TRYCATs pathway), with the production of various L-TRP catabolites, including kynurenine (KYN), and the reduction of plasma L-TRP concentration [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B13-life-10-00082">13</xref>,<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. As a result, it was suggested that the inflammation-induced increase of L-TRP degradation would be typical of depression and associated with an increase in TRYCAT catabolite production [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>], rather than a L-TRP/5-HT depletion, as previously supposed. </p>
<p>Animal models support the involvement of IDO activation in mood disorders pathophysiology [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. In a study on mice population, TRYCATs was able to trigger depressive and anxious behaviors [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>]. In addition, TRYCATs also showed neurotoxic effects: the KYN can be converted into quinolinic acid (QA), a potent N-methyl-D-aspartate (NMDA) agonist, which stimulates glutamate release resulting in lipid peroxidation [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. The consequences of glucocorticoids imbalance and resistance contribute, in turn, to the continuous secretion of pro-inflammatory cytokines. </p>
<p>Again, patients affected by hepatitis C who developed depressive symptoms under IFN-α treatment showed decreased blood L-TRP levels and increased blood KYN concentrations [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>] (<xref ref-type="fig" rid="life-10-00082-f004">Figure 4</xref>).</p>
</sec>
<sec id="sec5-life-10-00082">
<title>5. Stress-Induced Activation of the Inflammatory Response</title>
<p>Although neuro-inflammation seems to contribute to mood alterations [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>], the causal factors underlying it are currently unknown. In depressive states associated with inflammatory/immune system diseases, the pathophysiological factors might be the same involved in neuro-inflammation. However, in depression occurring in subjects with no medical comorbidity, stressful life events would play a critical role. Epidemiological studies on clinical and community samples showed a significant association between a history of early and/or recent stressful events and mood disorders [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. Moreover, psychosocial stressors demonstrated to be robust triggers of peripheral and central inflammation, both in animals and in humans [<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. In a study on rats under stressful conditions, increased concentrations of IL-1β and IL-6 were reported in the brain and blood [<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>]. In humans, some studies described increased production of IFNγ and TNFα during stress states [<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B38-life-10-00082">38</xref>]. Increased levels of CRP were linked to chronic stress conditions, including interpersonal conflicts and perceived stress, [<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B32-life-10-00082">32</xref>,<xref ref-type="bibr" rid="B37-life-10-00082">37</xref>,<xref ref-type="bibr" rid="B38-life-10-00082">38</xref>,<xref ref-type="bibr" rid="B91-life-10-00082">91</xref>], as well as to severe early life events, such as childhood abuse [<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. Further, increased IL-6 and NF-κB response to antigenic challenge and psychosocial stressors were detected in MDD patients [<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>].</p>
<p>For a long time, HPA dysfunctions have been considered one of the most relevant factors underlying the onset of depression, although their precise mechanisms have not yet been fully elucidated [<xref ref-type="bibr" rid="B92-life-10-00082">92</xref>,<xref ref-type="bibr" rid="B93-life-10-00082">93</xref>,<xref ref-type="bibr" rid="B94-life-10-00082">94</xref>]. In the central nervous system, glucocorticoids participate in the regulation of neuronal survival and neurogenesis, especially at the level of hippocampus, as well as to the modulation of memory processes and emotional learning [<xref ref-type="bibr" rid="B95-life-10-00082">95</xref>], in addition to regulating, through negative feedback, on limbic and hypothalamic areas, the release of corticotropin-releasing factor (CRF). At the peripheral level, glucocorticoids act by modulating the immune and inflammatory response through specific receptors located on the membranes of lymphocytes and leukocytes [<xref ref-type="bibr" rid="B96-life-10-00082">96</xref>]. The hypothalamus seems to be the brain area most involved in the inflammation trigger after psychosocial stress [<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. In particular, psychosocial stressors can induce hypothalamic release of catecholamines and CRH that act on the HPA axis. At the level of the immune system, the catecholamines, by increasing NF-κB expression, trigger the production of inflammatory cytokines [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>] that, in turn, after entering the brain, may cause the activation of microglia and consequent neuro-inflammation [<xref ref-type="bibr" rid="B32-life-10-00082">32</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. On the other hand, the release of CRH activates the HPA axis, followed, in physiological conditions, by the negative feedback on the release of CRH and the inhibition of inflammatory responses. In pathological conditions, as in the case of depression or chronic stress, the presence of a state of “glucocorticoid resistance”, possibly related to cytokines effects on glucocorticoid receptors, may lead to HPA axis hyper-activation and neuro-inflammation perpetuation [<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. Such phenomena would seem to provoke detrimental effects on the brain structures, and may underlie the brain damage possibly associated with MDD and BDs, as they cause monoamine metabolism alterations, decreased neurotrophism, and excitotoxicity [<xref ref-type="bibr" rid="B9-life-10-00082">9</xref>,<xref ref-type="bibr" rid="B10-life-10-00082">10</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. Different scholars reported increased cortisol levels in plasma, saliva, and urine of depressed patients, in some cases associated with an increased volume of pituitary and adrenal glands [<xref ref-type="bibr" rid="B97-life-10-00082">97</xref>,<xref ref-type="bibr" rid="B98-life-10-00082">98</xref>]. Mineralocorticoid receptors (MRs) may also play a role in HPA axis dysfunction in depression, such as the desensitization and loss of inhibition in HPA feedback [<xref ref-type="bibr" rid="B92-life-10-00082">92</xref>]. The consequences of glucocorticoids imbalance and resistance would contribute to the continuous secretion of pro-inflammatory cytokines, also altering the hippocampal microglia functions [<xref ref-type="bibr" rid="B99-life-10-00082">99</xref>]. The persistence of cytokine secretion, in turn, may lead to the activation of specific metabolic pathways, such as the shunt of TRP (also known as “kynurenine pathway”), with the production of QA stimulating the glutamatergic system and lowering 5-HT production [<xref ref-type="bibr" rid="B100-life-10-00082">100</xref>,<xref ref-type="bibr" rid="B101-life-10-00082">101</xref>]. In addition to inflammation and neurotransmitters, dysfunction of the HPA axis could negatively impact the production of neurotrophins and promote the oxidative stress [<xref ref-type="bibr" rid="B92-life-10-00082">92</xref>,<xref ref-type="bibr" rid="B93-life-10-00082">93</xref>,<xref ref-type="bibr" rid="B94-life-10-00082">94</xref>].</p>
<p>In conclusion, HPA axis hyperactivity, hypercortisolemia, induction of inflammatory patterns (such as the increase in circulating cytokines), stimulation of specific leukocyte populations, alterations of cardiovascular risk factors (such as CRP) and of platelet reactivity, could be part of the same mechanisms of depression.</p>
</sec>
<sec id="sec6-life-10-00082">
<title>6. Mood Disorders and Oxidative Stress</title>
<p>Different clinical and preclinical studies reported altered levels of oxidative stress markers in depression, such as reduced concentrations of non-enzymatic and enzymatic antioxidants, which can be normalized by AD treatment [<xref ref-type="bibr" rid="B102-life-10-00082">102</xref>,<xref ref-type="bibr" rid="B103-life-10-00082">103</xref>,<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. Moreover, some antioxidants (zinc, N-acetylcysteine, omega-3 free fatty acids) show some antidepressant properties [<xref ref-type="bibr" rid="B105-life-10-00082">105</xref>,<xref ref-type="bibr" rid="B106-life-10-00082">106</xref>]. The precise mechanisms underlying the altered redox responses in different forms of depression are not completely known. It has been hypothesized that monoaminergic, neurotrophic, and HPA axis dysfunctions may affect metabolic and redox mechanisms in depression. Moreover, a dysfunctional response to stressors may be related to inadequate lifestyle and dietary habits, with consequences on the anti-oxidant response and metabolic or nutritional conditions of depressed patients [<xref ref-type="bibr" rid="B107-life-10-00082">107</xref>,<xref ref-type="bibr" rid="B108-life-10-00082">108</xref>,<xref ref-type="bibr" rid="B109-life-10-00082">109</xref>,<xref ref-type="bibr" rid="B110-life-10-00082">110</xref>]. The antioxidant system consist of two main components: non-enzymatic antioxidants, such as glutathione, thiols (R-SH), plasma proteins, uric acid (UA), vitamin C, vitamin E, zinc and coenzyme Q10, and enzymatic antioxidants, such as superoxide dismutase (SOD), catalase, glutathione peroxidase and reductase, and thioredoxin system [<xref ref-type="bibr" rid="B102-life-10-00082">102</xref>,<xref ref-type="bibr" rid="B103-life-10-00082">103</xref>,<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. The main components protecting against brain damage caused by free radicals are antioxidant enzymes, expressed in both peripheral organs and the brain [<xref ref-type="bibr" rid="B102-life-10-00082">102</xref>,<xref ref-type="bibr" rid="B103-life-10-00082">103</xref>,<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. In any case, together with an altered immune-inflammatory response, the induction of oxidative stress, including reactive oxygen species (ROS) and reactive nitrogen species (RNS), appears to play a crucial role in aging and in the development of severe diseases, such as cancer, cardiovascular, and neurodegenerative disorders (e.g., Parkinson’s disease, Alzheimer’s disease and Huntington’s chorea) [<xref ref-type="bibr" rid="B111-life-10-00082">111</xref>,<xref ref-type="bibr" rid="B112-life-10-00082">112</xref>,<xref ref-type="bibr" rid="B113-life-10-00082">113</xref>,<xref ref-type="bibr" rid="B114-life-10-00082">114</xref>], as well as psychiatric disorders [<xref ref-type="bibr" rid="B115-life-10-00082">115</xref>,<xref ref-type="bibr" rid="B116-life-10-00082">116</xref>], including MDD and BDs [<xref ref-type="bibr" rid="B117-life-10-00082">117</xref>,<xref ref-type="bibr" rid="B118-life-10-00082">118</xref>,<xref ref-type="bibr" rid="B119-life-10-00082">119</xref>]. This is possibly due to the high vulnerability of the CNS to oxidative damage [<xref ref-type="bibr" rid="B102-life-10-00082">102</xref>,<xref ref-type="bibr" rid="B103-life-10-00082">103</xref>,<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. Indeed, the excessive production of reactive species, that at a low physiological concentration function as signaling molecules, and play a key role in regulating the immune cells activity, can significantly damage different cellular components, including proteins (receptors and enzymes), lipids, and DNA, eventually resulting in apoptosis and cell death. Moreover, ROS and RNS may alter important brain functions throughout the modulation of neurotransmitters, such as the glutamate involved in depression neurobiology [<xref ref-type="bibr" rid="B102-life-10-00082">102</xref>,<xref ref-type="bibr" rid="B110-life-10-00082">110</xref>]. In addition, ROS and RNS may act as triggers of autoimmune responses, altering the chemical structure of several molecules with the production of autoimmune epitopes. This is the case of the nitration of proteins that give rise to nitrotyrosine—a highly immunogenic neo-epitope. In the same way, the oxidation of auto-epitopes of fatty acids, normally ignored by immune cells, can lead to their recognition after the damage of the components of the lipid membranes [<xref ref-type="bibr" rid="B102-life-10-00082">102</xref>,<xref ref-type="bibr" rid="B103-life-10-00082">103</xref>,<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. In some cases of depression, altered concentrations of non-enzymatic antioxidants were revealed, such as decreased levels of vitamin E and coenzyme Q10. In a group of depressed patients, reduced levels of vitamin C or vitamin A at the baseline were normalized by ADs treatments [<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. However, these data are controversial, since other studies reported opposite findings (increased level of vitamin E and negative relation between vitamin C and severity of depression) [<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. Other studies showed different activity of antioxidants enzymes, including SOD, catalase, and glutathione peroxidase, in patients with MDD compared with healthy subjects. Most of the available data reported an increase of the SOD activity in depression [<xref ref-type="bibr" rid="B120-life-10-00082">120</xref>], but opposite results were also published [<xref ref-type="bibr" rid="B121-life-10-00082">121</xref>]. However, ADs might reduce the action of SOD that seems positively related to depression severity. In MDD, also, an increased catalase and glutathione-reductase activity and a decreased of glutathione-peroxidase response were revealed, with a normalization following ADs treatment [<xref ref-type="bibr" rid="B120-life-10-00082">120</xref>]. However, cases of reduced catalase activity were also described in depression [<xref ref-type="bibr" rid="B122-life-10-00082">122</xref>]. Again, in a group of subjects with a single depressive episode, the total antioxidant capacity was lower than the oxidative stress index, when compared with healthy subjects, but the values were normalized after the administration of specific treatments [<xref ref-type="bibr" rid="B104-life-10-00082">104</xref>]. A series of studies reported lipid oxidative damage in depression. A first study showed a decrease in polyunsaturated fatty acids (PUFAs) of red blood cell lipid membranes in depressed patients, indicating an increase in long chain degradation by peroxidation. Indeed, the oxidative potential index (OPI), calculated to measure the tendency of fatty acids to oxidize, was reduced in these subjects, suggesting a decreased oxidation capacity by the phospholipids with a consequent increase in long-chain degradation by peroxidation [<xref ref-type="bibr" rid="B105-life-10-00082">105</xref>,<xref ref-type="bibr" rid="B106-life-10-00082">106</xref>]. In acute forms of depression, some authors observed an increase in oxidative stress associated with DNA damage in blood, urine, and brain tissue, highlighted by a higher concentration of the oxidative stress indicator damage 8-hydroxy-guanine (8-OH-Gua) compared with the control group [<xref ref-type="bibr" rid="B105-life-10-00082">105</xref>,<xref ref-type="bibr" rid="B106-life-10-00082">106</xref>].</p>
<p>Overall, these data could reflect an altered reactivity of the antioxidant system in different mood disorders that, albeit interesting, require to be substantiated by more specific data [<xref ref-type="bibr" rid="B108-life-10-00082">108</xref>,<xref ref-type="bibr" rid="B123-life-10-00082">123</xref>].</p>
</sec>
<sec id="sec7-life-10-00082">
<title>7. Mood Disorders and Uric Acid</title>
<p>Together with the purines, UA, the final compound of purines catabolism, seems to play a leading role in many cell functions, regulating sleep/wake cycle, appetite, cognitive ability, memory, seizure threshold, social interaction, and impulsiveness [<xref ref-type="bibr" rid="B124-life-10-00082">124</xref>,<xref ref-type="bibr" rid="B125-life-10-00082">125</xref>]. Furthermore, purines and UA contribute to modulate energy metabolism and signal transduction, platelets, muscles, and neurotransmission physiology, cell growth, proliferation, and survival [<xref ref-type="bibr" rid="B126-life-10-00082">126</xref>]. Currently, it is also well known the role of ATP and adenosine (part of its catabolism) in different brain areas, including the cerebral cortex, hypothalamus, and the limbic system [<xref ref-type="bibr" rid="B127-life-10-00082">127</xref>], where they act as co-modulators of other neurotransmitters, such as γ-aminobutyric acid (GABA), dopamine, glutamate, and 5-HT, all involved in the pathophysiology of mood disorders [<xref ref-type="bibr" rid="B127-life-10-00082">127</xref>,<xref ref-type="bibr" rid="B128-life-10-00082">128</xref>,<xref ref-type="bibr" rid="B129-life-10-00082">129</xref>]. Different enzyme subtypes degrade ATP into adenosine and inosine. Adenosine can be absorbed by the terminal transporters of the nerve and broken down into inosine, transformed, in turn, in hypoxanthine and, finally, cleaved by xanthine oxidase (XO) to generate UA, its downstream product [<xref ref-type="bibr" rid="B130-life-10-00082">130</xref>]. In physiological conditions, there is a balance between the synthesis and degradation of purines [<xref ref-type="bibr" rid="B126-life-10-00082">126</xref>]. Over-production of UA proved to play an emerging role in different human diseases [<xref ref-type="bibr" rid="B126-life-10-00082">126</xref>], including neuropsychiatric disorders [<xref ref-type="bibr" rid="B124-life-10-00082">124</xref>,<xref ref-type="bibr" rid="B125-life-10-00082">125</xref>]. In previous years, several studies indicated the possible involvement of purinergic system dysregulations in mood disorders, as well as in neurodegenerative and neuro-inflammatory disorders (i.e., multiple sclerosis, seizures, migraine) often comorbid with depression [<xref ref-type="bibr" rid="B124-life-10-00082">124</xref>,<xref ref-type="bibr" rid="B125-life-10-00082">125</xref>,<xref ref-type="bibr" rid="B131-life-10-00082">131</xref>,<xref ref-type="bibr" rid="B132-life-10-00082">132</xref>,<xref ref-type="bibr" rid="B133-life-10-00082">133</xref>,<xref ref-type="bibr" rid="B134-life-10-00082">134</xref>,<xref ref-type="bibr" rid="B135-life-10-00082">135</xref>,<xref ref-type="bibr" rid="B136-life-10-00082">136</xref>,<xref ref-type="bibr" rid="B137-life-10-00082">137</xref>,<xref ref-type="bibr" rid="B138-life-10-00082">138</xref>,<xref ref-type="bibr" rid="B139-life-10-00082">139</xref>]. The correlation between bipolar spectrum disorders with gout and Lesch–Nyhan disease, as well as obesity, thyroid alterations, cardiovascular disease, and diabetes, has been known all along, suggesting an alteration of energy and metabolic processes in mood disorders [<xref ref-type="bibr" rid="B124-life-10-00082">124</xref>,<xref ref-type="bibr" rid="B125-life-10-00082">125</xref>,<xref ref-type="bibr" rid="B140-life-10-00082">140</xref>].</p>
<p>Kraepelin was the first to hypothesize the possible role of the purinergic system in mood disorders [<xref ref-type="bibr" rid="B141-life-10-00082">141</xref>], and that the excretion of UA in subjects with altered mood states was significantly reduced. Indeed, the purinergic system has been related to MDD, BD, and anxiety symptoms, including dysfunctional sleep, anhedonia, changes in appetite, energy and motor functions levels, as well as cognitive deficits and psychomotor agitation [<xref ref-type="bibr" rid="B124-life-10-00082">124</xref>]. During the 1970s, Brooks and colleagues [<xref ref-type="bibr" rid="B142-life-10-00082">142</xref>], basing their hypothesis on the rationale that UA clearance resulting from a significant turnover of purines in the brain, investigated peripheral UA in the attempt to identify a connection to specific mood symptoms. A significant correlation between UA and hallucinations, suicidality, and manic symptoms was observed, and the results led to a subsequent speculation that the purinergic system might be connected to mood dysregulation because of a dysfunction of ATP and/or adenosine due to a hereditary or neuro-inflammatory substrate [<xref ref-type="bibr" rid="B142-life-10-00082">142</xref>]. More recently, some studies investigated the peripheral levels of potential biomarkers of the purinergic system, particularly UA, in subjects affected by mood disorders. Interestingly, BD and MDD patients showed altered levels of serum UA, with higher concentrations during the manic phase [<xref ref-type="bibr" rid="B143-life-10-00082">143</xref>,<xref ref-type="bibr" rid="B144-life-10-00082">144</xref>,<xref ref-type="bibr" rid="B145-life-10-00082">145</xref>,<xref ref-type="bibr" rid="B146-life-10-00082">146</xref>] and lower during depressive phases. Furthermore, UA levels in depressed patients seem to normalize after a treatment with ADs [<xref ref-type="bibr" rid="B147-life-10-00082">147</xref>], some mood stabilizers (lithium [<xref ref-type="bibr" rid="B148-life-10-00082">148</xref>,<xref ref-type="bibr" rid="B149-life-10-00082">149</xref>], and carbamazepine [<xref ref-type="bibr" rid="B150-life-10-00082">150</xref>]). In addition, genetic studies suggest that some purinergic receptors subtypes could be involved in many aspects of behavior and mood dysregulation [<xref ref-type="bibr" rid="B148-life-10-00082">148</xref>]. Some single-nucleotide polymorphisms showed a significant association with an increased risk of mood disorders [<xref ref-type="bibr" rid="B151-life-10-00082">151</xref>]. Furthermore, a dysfunction of the downstream adenosine receptor was demonstrated in BD, highlighting an alteration of the levels of cAMP, protein kinase C, and intracellular Ca<sup>2+</sup> in manic patients. In agreement with this finding, a recent study showed that purinergic modulators seem to rapidly improve the clinical picture of mood disorders [<xref ref-type="bibr" rid="B128-life-10-00082">128</xref>,<xref ref-type="bibr" rid="B145-life-10-00082">145</xref>]. In vitro studies showed that ATP and adenosine could be potential targets for future treatments of mood disorders, and two inhibitors of the XO enzyme, allopurinol and febuxostat, showed an antidepressant effect, similar to fluoxetine, a selective serotonin reuptake inhibitor (SSRI) AD, in animal models [<xref ref-type="bibr" rid="B151-life-10-00082">151</xref>]. </p>
<p>The evidence that a dysfunctional purinergic system influence a multiplicity of central and peripheral processes supports the hypothesis that mood disorders could be re-considered as systemic diseases. Furthermore, in the view of a unified pathogenetic model of mood disorders, currently it is known that the purinergic system also takes part in neuro-inflammation and neurotoxicity mechanisms [<xref ref-type="bibr" rid="B152-life-10-00082">152</xref>,<xref ref-type="bibr" rid="B153-life-10-00082">153</xref>,<xref ref-type="bibr" rid="B154-life-10-00082">154</xref>,<xref ref-type="bibr" rid="B155-life-10-00082">155</xref>,<xref ref-type="bibr" rid="B156-life-10-00082">156</xref>]. Although the processes through which this occurs are still unclear, several studies show that a possible mediator could be represented by oxidative stress [<xref ref-type="bibr" rid="B157-life-10-00082">157</xref>,<xref ref-type="bibr" rid="B158-life-10-00082">158</xref>,<xref ref-type="bibr" rid="B159-life-10-00082">159</xref>,<xref ref-type="bibr" rid="B160-life-10-00082">160</xref>].</p>
<p>These preliminary data suggest the need to study biochemical mechanisms underlying purinergic dysfunctions, since these system components appear to be promising new therapeutic targets in mood disorders [<xref ref-type="bibr" rid="B144-life-10-00082">144</xref>,<xref ref-type="bibr" rid="B161-life-10-00082">161</xref>].</p>
</sec>
<sec id="sec8-life-10-00082">
<title>8. BDNF and Inflammatory Responses in Mood Disorders</title>
<p>For years, evidence has shown neurotrophin alterations in mood disorders, particularly in depression [<xref ref-type="bibr" rid="B162-life-10-00082">162</xref>,<xref ref-type="bibr" rid="B163-life-10-00082">163</xref>,<xref ref-type="bibr" rid="B164-life-10-00082">164</xref>,<xref ref-type="bibr" rid="B165-life-10-00082">165</xref>,<xref ref-type="bibr" rid="B166-life-10-00082">166</xref>]. Most studies on depression reported reduced serum and plasma BDNF levels in depressed patients, compared with controls [<xref ref-type="bibr" rid="B167-life-10-00082">167</xref>,<xref ref-type="bibr" rid="B168-life-10-00082">168</xref>,<xref ref-type="bibr" rid="B169-life-10-00082">169</xref>,<xref ref-type="bibr" rid="B170-life-10-00082">170</xref>,<xref ref-type="bibr" rid="B171-life-10-00082">171</xref>,<xref ref-type="bibr" rid="B172-life-10-00082">172</xref>,<xref ref-type="bibr" rid="B173-life-10-00082">173</xref>,<xref ref-type="bibr" rid="B174-life-10-00082">174</xref>,<xref ref-type="bibr" rid="B175-life-10-00082">175</xref>]. However, elevated plasma neurotrophin levels were also found [<xref ref-type="bibr" rid="B176-life-10-00082">176</xref>]. An increase of circulating BDNF was associated with depression familiarity [<xref ref-type="bibr" rid="B177-life-10-00082">177</xref>] mixed state episodes [<xref ref-type="bibr" rid="B178-life-10-00082">178</xref>], and to ADs administration [<xref ref-type="bibr" rid="B179-life-10-00082">179</xref>,<xref ref-type="bibr" rid="B180-life-10-00082">180</xref>,<xref ref-type="bibr" rid="B181-life-10-00082">181</xref>]. Again, a high baseline BDNF level was associated to a positive response to ADs [<xref ref-type="bibr" rid="B182-life-10-00082">182</xref>]. For these reasons, peripheral BDNF was proposed as a potential diagnostic, prognostic, and therapeutic biomarker for mood disorders, particularly associated with disease severity and response to AD treatments [<xref ref-type="bibr" rid="B181-life-10-00082">181</xref>,<xref ref-type="bibr" rid="B182-life-10-00082">182</xref>,<xref ref-type="bibr" rid="B183-life-10-00082">183</xref>]. However, results are still inconclusive [<xref ref-type="bibr" rid="B184-life-10-00082">184</xref>,<xref ref-type="bibr" rid="B185-life-10-00082">185</xref>,<xref ref-type="bibr" rid="B186-life-10-00082">186</xref>], as high blood BDNF levels were revealed also in resistant depression subjects under pharmacological treatment [<xref ref-type="bibr" rid="B44-life-10-00082">44</xref>]. In addition, many factors contributed to limiting peripheral BDNF as a reliable biomarker for mood disorders. Indeed, the BDNF production is ubiquitous in peripheral tissues, this neurotrophin is involved in a variety of body functions [<xref ref-type="bibr" rid="B187-life-10-00082">187</xref>,<xref ref-type="bibr" rid="B188-life-10-00082">188</xref>,<xref ref-type="bibr" rid="B189-life-10-00082">189</xref>,<xref ref-type="bibr" rid="B190-life-10-00082">190</xref>], and its expression and secretion are influenced by many internal and external factors. Moreover, the connection between peripheral and central BDNF is still currently unknown, and reduced blood BDNF levels have been reported in a multitude of neuropsychiatric and neurodegenerative diseases, as well as in medical diseases, making circulating BDNF a non-specific biomarker [<xref ref-type="bibr" rid="B191-life-10-00082">191</xref>,<xref ref-type="bibr" rid="B192-life-10-00082">192</xref>,<xref ref-type="bibr" rid="B193-life-10-00082">193</xref>,<xref ref-type="bibr" rid="B194-life-10-00082">194</xref>,<xref ref-type="bibr" rid="B195-life-10-00082">195</xref>,<xref ref-type="bibr" rid="B196-life-10-00082">196</xref>,<xref ref-type="bibr" rid="B197-life-10-00082">197</xref>,<xref ref-type="bibr" rid="B198-life-10-00082">198</xref>,<xref ref-type="bibr" rid="B199-life-10-00082">199</xref>,<xref ref-type="bibr" rid="B200-life-10-00082">200</xref>].</p>
<p>In recent years, research has focused on the possible relationships between neurotrophins, inflammation, and stress axis in the pathogenesis of mood disorders. Recent findings reported that BDNF is a key regulator in the neuro-immune axis regulation [<xref ref-type="bibr" rid="B201-life-10-00082">201</xref>]. However, its potential mechanism in mood disorders remains unclear [<xref ref-type="bibr" rid="B201-life-10-00082">201</xref>]. Several available data suggested that inflammatory state, promoted and presumably induced by an altered activation of the HPA axis, might contribute to the development and/or progression of the depressive pathology through an alteration of the neuroplasticity caused by reduced BDNF activity [<xref ref-type="bibr" rid="B202-life-10-00082">202</xref>,<xref ref-type="bibr" rid="B203-life-10-00082">203</xref>]. It is well known that inflammatory cytokines affect neuronal development and apoptosis [<xref ref-type="bibr" rid="B204-life-10-00082">204</xref>,<xref ref-type="bibr" rid="B205-life-10-00082">205</xref>] and, together with stress, could produce a negative effect on neurogenesis and neuroplasticity [<xref ref-type="bibr" rid="B206-life-10-00082">206</xref>,<xref ref-type="bibr" rid="B207-life-10-00082">207</xref>]. In laboratory animals, the infusion of LPS in the substantia nigra induced an anxious and depressed phenotype, together with a decrease of BDNF expression in the hippocampus [<xref ref-type="bibr" rid="B208-life-10-00082">208</xref>,<xref ref-type="bibr" rid="B209-life-10-00082">209</xref>]. In rat models, the injection of pro-inflammatory substances led to increased IL-1β, IL-6, and TNF-α expression and decreased BDNF-mRNA expression, particularly in the hippocampus [<xref ref-type="bibr" rid="B210-life-10-00082">210</xref>,<xref ref-type="bibr" rid="B211-life-10-00082">211</xref>]. IL-1β is a pro-inflammatory cytokines that seems to influence hippocampal cytogenesis and neurogenesis in two distinct ways: directly, by interacting with its IL-1R1 receptor and activating NF-kB, and indirectly, by stimulating the glucocorticoid secretion in response to environmental stress [<xref ref-type="bibr" rid="B202-life-10-00082">202</xref>]. </p>
<p>In humans, patients under treatment with IFN-α showed reduced systemic BDNF levels in combination with increased levels of the cytokines IL-1 and IL-2 [<xref ref-type="bibr" rid="B212-life-10-00082">212</xref>,<xref ref-type="bibr" rid="B213-life-10-00082">213</xref>]. Some studies suggested a role of IL-1β in reducing BDNF in patients with depression [<xref ref-type="bibr" rid="B212-life-10-00082">212</xref>], indicating that an increase in IL-1β concentrations was associated with a decrease in BDNF concentrations [<xref ref-type="bibr" rid="B212-life-10-00082">212</xref>]. However, it was also proposed that IL-1β could influence not only BDNF concentration, but also BDNF signaling pathways [<xref ref-type="bibr" rid="B214-life-10-00082">214</xref>]. Therefore, high IL-1β levels could alter the signal deriving from the binding of BDNF with its receptors, causing a sort of BDNF resistance despite its levels being normal or high [<xref ref-type="bibr" rid="B215-life-10-00082">215</xref>,<xref ref-type="bibr" rid="B216-life-10-00082">216</xref>]. This could explain the opposite results on the relation between inflammation and neurotrophins, and why in some cases of depression, despite drug treatment, there are high levels of BDNF. According to a recent study, even lipoproteins could decrease brain BDNF levels in the prefrontal regions and in the hippocampus, while increasing them in the nucleus accumbens [<xref ref-type="bibr" rid="B206-life-10-00082">206</xref>]. </p>
<p>Finally, as outlined above, an increase in microglia affecting different brain regions was observed in depressed patients. It was also described that microglia could regulate the release of BDNF and reduce the expression of BDNF and its affinity with tyrosine receptor kinase B (TrkB) receptor [<xref ref-type="bibr" rid="B201-life-10-00082">201</xref>]. Conversely, BDNF can promote glia growth and proliferation [<xref ref-type="bibr" rid="B217-life-10-00082">217</xref>,<xref ref-type="bibr" rid="B218-life-10-00082">218</xref>] and contribute to the chronic inflammatory state of the brain and neurotoxicity observed in several mood disorders [<xref ref-type="bibr" rid="B69-life-10-00082">69</xref>,<xref ref-type="bibr" rid="B70-life-10-00082">70</xref>,<xref ref-type="bibr" rid="B71-life-10-00082">71</xref>].</p>
<p>However, despite several ongoing studies, there are still no reliable data on the correlation between inflammatory events and the expression of specific BDNF genes [<xref ref-type="bibr" rid="B206-life-10-00082">206</xref>].</p>
</sec>
<sec id="sec9-life-10-00082" sec-type="conclusions">
<title>9. Conclusions</title>
<p>Nowadays, there is a general agreement that mood disorders are multifactorial disorders, whose physiopathology include a combination of intertwined genetic and/or acquired factors to define a variety of biological endophenotypes and clinical pictures [<xref ref-type="bibr" rid="B30-life-10-00082">30</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>]. These factors involve not only the brain, but also the whole organism. As a result, mood disorders are considered as systemic diseases [<xref ref-type="bibr" rid="B14-life-10-00082">14</xref>,<xref ref-type="bibr" rid="B15-life-10-00082">15</xref>,<xref ref-type="bibr" rid="B35-life-10-00082">35</xref>,<xref ref-type="bibr" rid="B39-life-10-00082">39</xref>]. Therefore, the changes in the monoamine system, described at the dawn of biological hypotheses of depression, are now being progressively integrated within a more complex and comprehensive model of mood disorders, including immune/inflammatory processes, oxidative and nitrosative stress, and changes in peripheral organs and tissues (i.e., the gut) [<xref ref-type="bibr" rid="B39-life-10-00082">39</xref>,<xref ref-type="bibr" rid="B77-life-10-00082">77</xref>].</p>
<p>In recent years, the involvement of the immune/inflammatory system in mood disorder development has become increasingly relevant, since many studies demonstrated mutual association between inflammatory diseases/biomarkers and mood alterations. Furthermore, more efforts are now directed towards the interactions between inflammation mechanisms and other systems and processes that, all together, might contribute to the pathophysiology of mood disorders and to their complex clinical features. In particular, inflammatory alterations associated with neurotransmitters and neurotrophins dysfunctions, chronic HPA axis activation, purinergic system abnormalities, and increased oxidative stress. It has also been noted that these factors may have different weights in individual cases, probably influencing the different clinical and prognostic characteristics of the disease, as well as the different response to drug treatment [<xref ref-type="bibr" rid="B178-life-10-00082">178</xref>,<xref ref-type="bibr" rid="B219-life-10-00082">219</xref>].</p>
<p>Along this view, biomarkers of every factor, possibly involved in the pathophysiology of mood disorders, could be useful to stratify patients based on the mechanism underlying their clinical picture, and to understand which specific groups could benefit from promising treatments based on new drug targets, such as anti-inflammatory treatments [<xref ref-type="bibr" rid="B220-life-10-00082">220</xref>,<xref ref-type="bibr" rid="B221-life-10-00082">221</xref>,<xref ref-type="bibr" rid="B222-life-10-00082">222</xref>]. </p>
<p>Therefore, to reach a complete management of mood disorders, it would be necessary to verify all the neurochemical, neurobiological, and metabolic factors that "shape" their presentations, in order to identify potential diagnostic, prognostic, and response biomarkers for treatment. Blood biomarkers seem the most promising [<xref ref-type="bibr" rid="B223-life-10-00082">223</xref>], being reliable, non-invasive, simple to perform, often inexpensive, and employed to categorize, exactly, the population in line with the disease [<xref ref-type="bibr" rid="B224-life-10-00082">224</xref>,<xref ref-type="bibr" rid="B225-life-10-00082">225</xref>]. Such strategies would perhaps represent an important step towards precision medicine in psychiatry.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This review study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>D.M., Federico Mucci (F.M.), Paolo Morana (P.M.), B.M., Florinda Morana (F.M.), and Paola Mangiapane (P.M.) planned the review study. D.M., Federico Mucci (F.M.), B.C., A.D.V., S.B., and L.D. revised all the specific literature. D.M., Federico Mucci (F.M.), and A.D.V. wrote the first version of the paper that was subsequently revised and approved from all authors. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-life-10-00082">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kieling</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McGorry</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Horton</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sargent</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Reducing the global burden of depression: A Lancet-World Psychiatric Association Commission</article-title>
<source/>Lancet
          <year>2019</year>
<volume>393</volume>
<fpage>e42</fpage>
<lpage>e43</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(18)32408-5</pub-id>
<pub-id pub-id-type="pmid">30482607</pub-id>
</element-citation>
</ref>
<ref id="B2-life-10-00082">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baldessarini</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>G.H.</given-names>
</name>
<name>
<surname>Tondo</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Bipolar depression: A major unsolved challenge</article-title>
<source/>Int. J. Bipolar Disord.
          <year>2020</year>
<volume>8</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/s40345-019-0160-1</pub-id>
<pub-id pub-id-type="pmid">31903509</pub-id>
</element-citation>
</ref>
<ref id="B3-life-10-00082">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Price</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Marzani-Nissen</surname>
<given-names>G.R.</given-names>
</name>
</person-group>
<article-title>Bipolar disorders: A review</article-title>
<source/>Am. Fam. Physician
          <year>2012</year>
<volume>85</volume>
<fpage>483</fpage>
<lpage>493</lpage>
<pub-id pub-id-type="pmid">22534227</pub-id>
</element-citation>
</ref>
<ref id="B4-life-10-00082">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malhi</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Depression</article-title>
<source/>Lancet
          <year>2018</year>
<volume>392</volume>
<fpage>2299</fpage>
<lpage>2312</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(18)31948-2</pub-id>
<pub-id pub-id-type="pmid">30396512</pub-id>
</element-citation>
</ref>
<ref id="B5-life-10-00082">
<label>5.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders
          <edition>5th ed.</edition>
<publisher-name>American Psychiatric Association Press</publisher-name>
<publisher-loc>Washington, DC, USA</publisher-loc>
<year>2013</year>
</element-citation>
</ref>
<ref id="B6-life-10-00082">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koukopoulos</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sani</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>DSM-5 criteria for depression with mixed features: A farewell to mixed depression</article-title>
<source/>Acta Psychiatr. Scand.
          <year>2014</year>
<volume>129</volume>
<fpage>4</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1111/acps.12140</pub-id>
<pub-id pub-id-type="pmid">23600771</pub-id>
</element-citation>
</ref>
<ref id="B7-life-10-00082">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vieta</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schulze</surname>
<given-names>T.G.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Suppes</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Calabrese</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miskowiak</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Grande</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Bipolar Disorders</article-title>
<source/>Nat. Rev. Dis. Premers.
          <year>2018</year>
<volume>8</volume>
<fpage>18008</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2018.8</pub-id>
<pub-id pub-id-type="pmid">29516993</pub-id>
</element-citation>
</ref>
<ref id="B8-life-10-00082">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Angst</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The bipolar spectrum</article-title>
<source/>Br. J. Psychiatry
          <year>2007</year>
<volume>190</volume>
<fpage>189</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.106.030957</pub-id>
<pub-id pub-id-type="pmid">17329735</pub-id>
</element-citation>
</ref>
<ref id="B9-life-10-00082">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dell’Osso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carmassi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mucci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Depression, serotonin and tryptophan</article-title>
<source/>Curr. Pharm. Des.
          <year>2016</year>
<volume>22</volume>
<fpage>949</fpage>
<lpage>954</lpage>
<pub-id pub-id-type="doi">10.2174/1381612822666151214104826</pub-id>
<pub-id pub-id-type="pmid">26654774</pub-id>
</element-citation>
</ref>
<ref id="B10-life-10-00082">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Abate</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Abate</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Abay</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Abbafati</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Abbasi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Abdollahpour</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study</article-title>
<source/>Lancet
          <year>2017</year>
<volume>392</volume>
<fpage>1789</fpage>
<lpage>1858</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(18)32279-7</pub-id>
</element-citation>
</ref>
<ref id="B11-life-10-00082">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Demler</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Koretz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Merikangas</surname>
<given-names>K.R.</given-names>
</name>
<name>
<surname>Rush</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.S.</given-names>
</name>
</person-group>
<article-title>The epidemiology of major depressive disorder results from the national comorbidity survey replication (NCS-R)</article-title>
<source/>JAMA
          <year>2003</year>
<volume>289</volume>
<fpage>3095</fpage>
<lpage>3105</lpage>
<pub-id pub-id-type="doi">10.1001/jama.289.23.3095</pub-id>
<pub-id pub-id-type="pmid">12813115</pub-id>
</element-citation>
</ref>
<ref id="B12-life-10-00082">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akiskal</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>The evolving bipolar spectrum. Prototypes I, II, III, and IV</article-title>
<source/>Psychiatr. Clin. N. Am.
          <year>1999</year>
<volume>22</volume>
<fpage>517</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1016/S0193-953X(05)70093-9</pub-id>
</element-citation>
</ref>
<ref id="B13-life-10-00082">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catena-Dell’Osso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rotella</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Dell’Osso</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fagiolini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Inflammation, serotonin and major depression</article-title>
<source/>Curr. Drug Targets
          <year>2013</year>
<volume>14</volume>
<fpage>571</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="doi">10.2174/13894501113149990154</pub-id>
<pub-id pub-id-type="pmid">23531160</pub-id>
</element-citation>
</ref>
<ref id="B14-life-10-00082">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catena-Dell’Osso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rotella</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bellantuono</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Emerging targets for the pharmacological treatment of depression: Focus on melatonergic system</article-title>
<source/>Curr. Med. Chem.
          <year>2012</year>
<volume>19</volume>
<fpage>428</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.2174/092986712803414277</pub-id>
<pub-id pub-id-type="pmid">22335516</pub-id>
</element-citation>
</ref>
<ref id="B15-life-10-00082">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catena-Dell’Osso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fagiolini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Baroni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bellantuono</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Non-monoaminergic targets for the development of antidepressants: Focus on neuropeptides</article-title>
<source/>Mini Rev. Med. Chem.
          <year>2013</year>
<volume>13</volume>
<fpage>2</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.2174/138955713804484758</pub-id>
<pub-id pub-id-type="pmid">22876945</pub-id>
</element-citation>
</ref>
<ref id="B16-life-10-00082">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Woelfer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Role of inflammation in depression relapse</article-title>
<source/>J. Neuroinflamm.
          <year>2019</year>
<volume>16</volume>
<fpage>90</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-019-1475-7</pub-id>
<pub-id pub-id-type="pmid">30995920</pub-id>
</element-citation>
</ref>
<ref id="B17-life-10-00082">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Metts</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Rubin-Falcone</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ogden</surname>
<given-names>R.T.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wilner</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Sublette</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Oquendo</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Antidepressant medication exposure and 5-HT1A autoreceptor binding in major depressive disorder</article-title>
<source/>Synapse
          <year>2019</year>
<volume>73</volume>
<fpage>e22089</fpage>
<pub-id pub-id-type="doi">10.1002/syn.22089</pub-id>
<pub-id pub-id-type="pmid">30693567</pub-id>
</element-citation>
</ref>
<ref id="B18-life-10-00082">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dold</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kasper</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Evidence-based pharmacotherapy of treatment-resistant unipolar depression</article-title>
<source/>Int. J. Psychiatry Clin. Pract.
          <year>2017</year>
<volume>21</volume>
<fpage>13</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1080/13651501.2016.1248852</pub-id>
<pub-id pub-id-type="pmid">27848269</pub-id>
</element-citation>
</ref>
<ref id="B19-life-10-00082">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>M.J.F.</given-names>
</name>
<name>
<surname>Boulle</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Steinbusch</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>van den Hove</surname>
<given-names>D.L.A.</given-names>
</name>
<name>
<surname>Kenis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lanfumey</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression</article-title>
<source/>Psychopharmacology
          <year>2018</year>
<volume>235</volume>
<fpage>2195</fpage>
<lpage>2220</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-018-4950-4</pub-id>
<pub-id pub-id-type="pmid">29961124</pub-id>
</element-citation>
</ref>
<ref id="B20-life-10-00082">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chávez-Castillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Núñez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nava</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ortega</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rojas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bermúdez</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Rojas-Quintero</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Depression as a neuroendocrine disorder: Emerging neuropsychopharmacological approaches beyond monoamines</article-title>
<source/>Adv. Pharmacol. Sci.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1155/2019/7943481</pub-id>
</element-citation>
</ref>
<ref id="B21-life-10-00082">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sigitova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fisar</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hroudova</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cikankova</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Raboch</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Biological hypotheses and biomarkers of bipolar disorder</article-title>
<source/>Psychiatry Clin. Neurosci.
          <year>2017</year>
<volume>71</volume>
<fpage>77</fpage>
<lpage>103</lpage>
<pub-id pub-id-type="doi">10.1111/pcn.12476</pub-id>
<pub-id pub-id-type="pmid">27800654</pub-id>
</element-citation>
</ref>
<ref id="B22-life-10-00082">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>New hypothesis and treatment targets of depression: An integrated view of key findings</article-title>
<source/>Neurosci. Bull.
          <year>2015</year>
<volume>31</volume>
<fpage>61</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1007/s12264-014-1486-4</pub-id>
<pub-id pub-id-type="pmid">25575479</pub-id>
</element-citation>
</ref>
<ref id="B23-life-10-00082">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.M.</given-names>
</name>
</person-group>
<article-title>Dendritic spines in depression: What we learned from animal models</article-title>
<source/>Neural Plast.
          <year>2016</year>
<volume>2016</volume>
<fpage>8056370</fpage>
<pub-id pub-id-type="doi">10.1155/2016/8056370</pub-id>
<pub-id pub-id-type="pmid">26881133</pub-id>
</element-citation>
</ref>
<ref id="B24-life-10-00082">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Hippocampal proteomic changes of susceptibility and resilience to depression or anxiety in a rat model of chronic mild stress</article-title>
<source/>Transl. Psychiatry
          <year>2019</year>
<volume>9</volume>
<fpage>260</fpage>
<pub-id pub-id-type="doi">10.1038/s41398-019-0605-4</pub-id>
<pub-id pub-id-type="pmid">31624233</pub-id>
</element-citation>
</ref>
<ref id="B25-life-10-00082">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sapolsky</surname>
<given-names>R.M.</given-names>
</name>
</person-group>
<article-title>Depression, antidepressants, and the shrinking hippocampus</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2001</year>
<volume>98</volume>
<fpage>12320</fpage>
<lpage>12322</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.231475998</pub-id>
<pub-id pub-id-type="pmid">11675480</pub-id>
</element-citation>
</ref>
<ref id="B26-life-10-00082">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Shoemark</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Barua</surname>
<given-names>N.U.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N.K.</given-names>
</name>
</person-group>
<article-title>GDNF, NGF and BDNF as therapeutic options for neurodegeneration</article-title>
<source/>Pharmacol. Ther.
          <year>2013</year>
<volume>138</volume>
<fpage>155</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.01.004</pub-id>
<pub-id pub-id-type="pmid">23348013</pub-id>
</element-citation>
</ref>
<ref id="B27-life-10-00082">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Popova</surname>
<given-names>N.K.</given-names>
</name>
<name>
<surname>Ilchibaeva</surname>
<given-names>T.V.</given-names>
</name>
<name>
<surname>Naumenko</surname>
<given-names>V.S.</given-names>
</name>
</person-group>
<article-title>Neurotrophic factors (BDNF and GDNF) and the serotonergic system of the brain</article-title>
<source/>Biochemistry
          <year>2017</year>
<volume>82</volume>
<fpage>308</fpage>
<lpage>317</lpage>
<pub-id pub-id-type="doi">10.1134/S0006297917030099</pub-id>
<pub-id pub-id-type="pmid">28320272</pub-id>
</element-citation>
</ref>
<ref id="B28-life-10-00082">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caspi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sugden</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Moffitt</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Craig</surname>
<given-names>I.W.</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>McClay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Braithwaite</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene</article-title>
<source/>Science
          <year>2003</year>
<volume>301</volume>
<fpage>386</fpage>
<lpage>389</lpage>
<pub-id pub-id-type="doi">10.1126/science.1083968</pub-id>
<pub-id pub-id-type="pmid">12869766</pub-id>
</element-citation>
</ref>
<ref id="B29-life-10-00082">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayberg</surname>
<given-names>H.S.</given-names>
</name>
</person-group>
<article-title>Limbic-cortical dysregulation: A proposed model of depression</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>1997</year>
<volume>9</volume>
<fpage>471</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1176/jnp.9.3.471</pub-id>
<pub-id pub-id-type="pmid">9276848</pub-id>
</element-citation>
</ref>
<ref id="B30-life-10-00082">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C.L.</given-names>
</name>
</person-group>
<article-title>The role of inflammation in depression: From evolutionary imperative to modern treatment target</article-title>
<source/>Nat. Rev. Immunol.
          <year>2016</year>
<volume>16</volume>
<fpage>22</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1038/nri.2015.5</pub-id>
<pub-id pub-id-type="pmid">26711676</pub-id>
</element-citation>
</ref>
<ref id="B31-life-10-00082">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>The effects of HPA axis function on cognition and its implications for the pathophysiology of bipolar disorder</article-title>
<source/>Harv. Rev. Psychiatry
          <year>2014</year>
<volume>22</volume>
<fpage>331</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="doi">10.1097/HRP.0000000000000020</pub-id>
<pub-id pub-id-type="pmid">25377604</pub-id>
</element-citation>
</ref>
<ref id="B32-life-10-00082">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haroon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Psychoneuroimmunology meets neuropsychopharmacology: Translational implications of the impact of inflammation on behavior</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<fpage>137</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2011.205</pub-id>
<pub-id pub-id-type="pmid">21918508</pub-id>
</element-citation>
</ref>
<ref id="B33-life-10-00082">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Barberi</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Mucci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maglio</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dell’Oste</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dell’Osso</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The emerging role of atrial natriuretic peptide in psychiatry</article-title>
<source/>Curr. Med. Chem.
          <year>2020</year>
<pub-id pub-id-type="doi">10.2174/0929867327666200219091102</pub-id>
</element-citation>
</ref>
<ref id="B34-life-10-00082">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liberati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>D.G.</given-names>
</name>
<collab>PRISMA Group</collab>
</person-group>
<article-title>Preferred reporting items for systematic reviews and meta analyses: The PRISMA statement</article-title>
<source/>PLoS Med.
          <year>2009</year>
<volume>6</volume>
<elocation-id>e1000097</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id>
<pub-id pub-id-type="pmid">19621072</pub-id>
</element-citation>
</ref>
<ref id="B35-life-10-00082">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenblat</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Bipolar disorder and immune dysfunction: Epidemiological findings, proposed pathophysiology and clinical implications</article-title>
<source/>Brain Sci.
          <year>2017</year>
<volume>7</volume>
<elocation-id>144</elocation-id>
<pub-id pub-id-type="doi">10.3390/brainsci7110144</pub-id>
<pub-id pub-id-type="pmid">29084144</pub-id>
</element-citation>
</ref>
<ref id="B36-life-10-00082">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mucci</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fontenelle</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Immune system and obsessive-compulsive disorder</article-title>
<source/>Psychoneuroendocrinology
          <year>2018</year>
<volume>93</volume>
<fpage>39</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2018.04.013</pub-id>
<pub-id pub-id-type="pmid">29689421</pub-id>
</element-citation>
</ref>
<ref id="B37-life-10-00082">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bosmans</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Scharpe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Suy</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Interleukin-1 beta: A putative mediator of HPA axis hyperactivity in major depression?</article-title>
<source/>Am. J. Psychiatry
          <year>1993</year>
<volume>150</volume>
<fpage>1189</fpage>
<lpage>1193</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.150.8.1189</pub-id>
<pub-id pub-id-type="pmid">8328562</pub-id>
</element-citation>
</ref>
<ref id="B38-life-10-00082">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Scharpe</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The monocyte-T-lymphocyte hypothesis of major depression</article-title>
<source/>Psychoneuroendocrinology
          <year>1995</year>
<volume>20</volume>
<fpage>111</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1016/0306-4530(94)00066-J</pub-id>
<pub-id pub-id-type="pmid">7899532</pub-id>
</element-citation>
</ref>
<ref id="B39-life-10-00082">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The cytokine hypothesis of depression: Inflammation, oxidative &amp; nitrosative stress (IO&amp;NS) and leaky gut as new targets for adjunctive treatments in depression</article-title>
<source/>Neuro Endocrinol. Lett.
          <year>2008</year>
<volume>29</volume>
<fpage>287</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="pmid">18580840</pub-id>
</element-citation>
</ref>
<ref id="B40-life-10-00082">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberger</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Moieni</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Inflammation affects social experience: Implications for mental health</article-title>
<source/>World Psychiatry
          <year>2020</year>
<volume>19</volume>
<fpage>109</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1002/wps.20724</pub-id>
<pub-id pub-id-type="pmid">31922673</pub-id>
</element-citation>
</ref>
<ref id="B41-life-10-00082">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amodeo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Trusso</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Fagiolini</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Depression and inflammation: Disentangling a clear yet complex and multifaceted link</article-title>
<source/>Neuropsychiatry
          <year>2018</year>
<volume>7</volume>
<fpage>448</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="doi">10.4172/Neuropsychiatry.1000236</pub-id>
</element-citation>
</ref>
<ref id="B42-life-10-00082">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cowen</surname>
<given-names>P.J.</given-names>
</name>
</person-group>
<article-title>Cortisol, serotonin and depression: All stressed out?</article-title>
<source/>Br. J. Psychiatry
          <year>2002</year>
<volume>180</volume>
<fpage>99</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.180.2.99</pub-id>
<pub-id pub-id-type="pmid">11823315</pub-id>
</element-citation>
</ref>
<ref id="B43-life-10-00082">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iwata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ota</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>The inflammasome: Pathways linking psychological stress, depression, and systemic illnesses</article-title>
<source/>Brain Behav. Immun.
          <year>2013</year>
<volume>31</volume>
<fpage>105</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2012.12.008</pub-id>
<pub-id pub-id-type="pmid">23261775</pub-id>
</element-citation>
</ref>
<ref id="B44-life-10-00082">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uint</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bastos</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Thurow</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Borges</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>T.D.C.</given-names>
</name>
<name>
<surname>França</surname>
<given-names>J.I.D.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>A.G.d.M.R.</given-names>
</name>
</person-group>
<article-title>Increased levels of plasma IL-1b and BDNF can predict resistant depression patients</article-title>
<source/>Rev. Assoc. Med. Bras.
          <year>2019</year>
<volume>65</volume>
<fpage>361</fpage>
<lpage>369</lpage>
<pub-id pub-id-type="doi">10.1590/1806-9282.65.3.361</pub-id>
<pub-id pub-id-type="pmid">30994834</pub-id>
</element-citation>
</ref>
<ref id="B45-life-10-00082">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Strowig</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Henao-Mejia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Elinav</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Flavell</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Inflammasomes in health and disease</article-title>
<source/>Nature
          <year>2012</year>
<volume>481</volume>
<fpage>278</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1038/nature10759</pub-id>
<pub-id pub-id-type="pmid">22258606</pub-id>
</element-citation>
</ref>
<ref id="B46-life-10-00082">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alcocer-Gomez</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>de Miguel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Casas-Barquero</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nunez-Vasco</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sanchez-Alcazar</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Fernandez-Rodriguez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cordero</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder</article-title>
<source/>Brain Behav. Immun.
          <year>2014</year>
<volume>36</volume>
<fpage>111</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2013.10.017</pub-id>
<pub-id pub-id-type="pmid">24513871</pub-id>
</element-citation>
</ref>
<ref id="B47-life-10-00082">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modabbernia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taslimi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brietzke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ashrafi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies</article-title>
<source/>Biol. Psychiatry
          <year>2013</year>
<volume>74</volume>
<fpage>15</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2013.01.007</pub-id>
<pub-id pub-id-type="pmid">23419545</pub-id>
</element-citation>
</ref>
<ref id="B48-life-10-00082">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munkholm</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Vinberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vedel Kessing</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Cytokines in bipolar disorder: A systematic review and meta-analysis</article-title>
<source/>J. Affect. Disord.
          <year>2013</year>
<volume>144</volume>
<fpage>16</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2012.06.010</pub-id>
<pub-id pub-id-type="pmid">22749156</pub-id>
</element-citation>
</ref>
<ref id="B49-life-10-00082">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbosa</surname>
<given-names>I.G.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Machado-Vieira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Cytokines in bipolar disorder: Paving the way for neuroprogression</article-title>
<source/>Neural Plast.
          <year>2014</year>
<volume>2014</volume>
<fpage>360481</fpage>
<pub-id pub-id-type="doi">10.1155/2014/360481</pub-id>
<pub-id pub-id-type="pmid">25313338</pub-id>
</element-citation>
</ref>
<ref id="B50-life-10-00082">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brietzke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stertz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Kauer-Sant’anna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mascarenhas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Escosteguy Vargas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chies</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder</article-title>
<source/>J. Affect. Disord.
          <year>2009</year>
<volume>116</volume>
<fpage>214</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2008.12.001</pub-id>
<pub-id pub-id-type="pmid">19251324</pub-id>
</element-citation>
</ref>
<ref id="B51-life-10-00082">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siwek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sowa-Kucma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Styczen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Misztak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dudek</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rybakowski</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder</article-title>
<source/>Mol. Neurobiol.
          <year>2017</year>
<volume>54</volume>
<fpage>5883</fpage>
<lpage>5893</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-016-0124-8</pub-id>
<pub-id pub-id-type="pmid">27660275</pub-id>
</element-citation>
</ref>
<ref id="B52-life-10-00082">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberger</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Moieni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Muscatell</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>In sickness and in health: The co-regulation of inflammation and social behavior</article-title>
<source/>Neuropsychopharmacology
          <year>2017</year>
<volume>42</volume>
<fpage>242</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2016.141</pub-id>
<pub-id pub-id-type="pmid">27480575</pub-id>
</element-citation>
</ref>
<ref id="B53-life-10-00082">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munkholm</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Brauner</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Kessing</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Vinberg</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis</article-title>
<source/>J. Psychiatr. Res.
          <year>2013</year>
<volume>47</volume>
<fpage>1119</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.018</pub-id>
<pub-id pub-id-type="pmid">23768870</pub-id>
</element-citation>
</ref>
<ref id="B54-life-10-00082">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres-Platas</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Cruceanu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.G.</given-names>
</name>
<name>
<surname>Turecki</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mechawar</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides</article-title>
<source/>Brain Behav. Immun.
          <year>2014</year>
<volume>42</volume>
<fpage>50</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2014.05.007</pub-id>
<pub-id pub-id-type="pmid">24858659</pub-id>
</element-citation>
</ref>
<ref id="B55-life-10-00082">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bielau</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Brisch</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Danos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ullrich</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Mawrin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>H.G.</given-names>
</name>
<name>
<surname>Bogerts</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Immunological aspects in the neurobiology of suicide: Elevated microglial density in schizophrenia and depression is associated with suicide</article-title>
<source/>J. Psychiatr. Res.
          <year>2008</year>
<volume>42</volume>
<fpage>151</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2006.10.013</pub-id>
<pub-id pub-id-type="pmid">17174336</pub-id>
</element-citation>
</ref>
<ref id="B56-life-10-00082">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muller</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Myint</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Inflammatory biomarkers and depression</article-title>
<source/>Neurotox. Res.
          <year>2011</year>
<volume>19</volume>
<fpage>308</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1007/s12640-010-9210-2</pub-id>
<pub-id pub-id-type="pmid">20658274</pub-id>
</element-citation>
</ref>
<ref id="B57-life-10-00082">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenblat</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>McIntyre</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Bipolar Disorder and Inflammation</article-title>
<source/>Psychiatr. Clin. N. Am.
          <year>2016</year>
<volume>39</volume>
<fpage>125</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1016/j.psc.2015.09.006</pub-id>
</element-citation>
</ref>
<ref id="B58-life-10-00082">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheline</surname>
<given-names>Y.I.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Gado</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Csernansky</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Vannier</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>Hippocampal atrophy in recurrent major depression</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1996</year>
<volume>93</volume>
<fpage>3908</fpage>
<lpage>3913</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.93.9.3908</pub-id>
<pub-id pub-id-type="pmid">8632988</pub-id>
</element-citation>
</ref>
<ref id="B59-life-10-00082">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheline</surname>
<given-names>Y.I.</given-names>
</name>
<name>
<surname>Gado</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Amygdala core nuclei volumes are decreased in recurrent major depression</article-title>
<source/>Neuroreport
          <year>1998</year>
<volume>9</volume>
<fpage>2023</fpage>
<lpage>2028</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-199806220-00021</pub-id>
<pub-id pub-id-type="pmid">9674587</pub-id>
</element-citation>
</ref>
<ref id="B60-life-10-00082">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campbell</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>MacQueen</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>An update on regional brain volume differences associated with mood disorders</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2006</year>
<volume>19</volume>
<fpage>25</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1097/01.yco.0000194371.47685.f2</pub-id>
<pub-id pub-id-type="pmid">16612175</pub-id>
</element-citation>
</ref>
<ref id="B61-life-10-00082">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonaccorso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Puzella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pasquini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Artini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Almerighi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Levrero</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Egyed</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bosmans</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms</article-title>
<source/>Psychiatry Res.
          <year>2001</year>
<volume>105</volume>
<fpage>45</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-1781(01)00315-8</pub-id>
<pub-id pub-id-type="pmid">11740974</pub-id>
</element-citation>
</ref>
<ref id="B62-life-10-00082">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonaccorso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Grimaldi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ippoliti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus</article-title>
<source/>J. Affect. Disord.
          <year>2002</year>
<volume>72</volume>
<fpage>237</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-0327(02)00264-1</pub-id>
<pub-id pub-id-type="pmid">12450640</pub-id>
</element-citation>
</ref>
<ref id="B63-life-10-00082">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonaccorso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Puzella</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pasquini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Artini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Almerighi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Verkerk</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2002</year>
<volume>22</volume>
<fpage>86</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1097/00004714-200202000-00014</pub-id>
<pub-id pub-id-type="pmid">11799348</pub-id>
</element-citation>
</ref>
<ref id="B64-life-10-00082">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capuron</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gumnick</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Musselman</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Lawson</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Reemsnyder</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions</article-title>
<source/>Neuropsychopharmacology
          <year>2002</year>
<volume>26</volume>
<fpage>643</fpage>
<lpage>652</lpage>
<pub-id pub-id-type="doi">10.1016/S0893-133X(01)00407-9</pub-id>
<pub-id pub-id-type="pmid">11927189</pub-id>
</element-citation>
</ref>
<ref id="B65-life-10-00082">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reichenberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yirmiya</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schuld</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kraus</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Haack</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morag</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pollmacher</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Cytokine-associated emotional and cognitive disturbances in humans</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2001</year>
<volume>58</volume>
<fpage>445</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.58.5.445</pub-id>
<pub-id pub-id-type="pmid">11343523</pub-id>
</element-citation>
</ref>
<ref id="B66-life-10-00082">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harrison</surname>
<given-names>N.A.</given-names>
</name>
<name>
<surname>Brydon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Steptoe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Critchley</surname>
<given-names>H.D.</given-names>
</name>
</person-group>
<article-title>Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity</article-title>
<source/>Biol. Psychiatry
          <year>2009</year>
<volume>66</volume>
<fpage>407</fpage>
<lpage>414</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2009.03.015</pub-id>
<pub-id pub-id-type="pmid">19423079</pub-id>
</element-citation>
</ref>
<ref id="B67-life-10-00082">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberger</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Mashal</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Inflammation and social experience: An inflammatory challenge induces feelings of social disconnection in addition to depressed mood</article-title>
<source/>Brain Behav. Immun.
          <year>2010</year>
<volume>24</volume>
<fpage>558</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2009.12.009</pub-id>
<pub-id pub-id-type="pmid">20043983</pub-id>
</element-citation>
</ref>
<ref id="B68-life-10-00082">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moieni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Jevtic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Olmstead</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Eisenberger</surname>
<given-names>N.I.</given-names>
</name>
</person-group>
<article-title>Sex differences in depressive and socioemotional responses to an inflammatory challenge: Implications for sex differences in depression</article-title>
<source/>Neuropsychopharmacology
          <year>2015</year>
<volume>40</volume>
<fpage>1709</fpage>
<lpage>1716</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2015.17</pub-id>
<pub-id pub-id-type="pmid">25598426</pub-id>
</element-citation>
</ref>
<ref id="B69-life-10-00082">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenberger</surname>
<given-names>N.I.</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Rameson</surname>
<given-names>L.T.</given-names>
</name>
<name>
<surname>Mashal</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>An fMRI study of cytokine-induced depressed mood and social pain: The role of sex differences</article-title>
<source/>Neuroimage
          <year>2009</year>
<volume>47</volume>
<fpage>881</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.04.040</pub-id>
<pub-id pub-id-type="pmid">19376240</pub-id>
</element-citation>
</ref>
<ref id="B70-life-10-00082">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muscatell</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Moieni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Inagaki</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Dutcher</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Jevtic</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Irwin</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Eisenberger</surname>
<given-names>N.I.</given-names>
</name>
</person-group>
<article-title>Exposure to an inflammatory challenge enhances neural sensitivity to negative and positive social feedback</article-title>
<source/>Brain Behav. Immun.
          <year>2016</year>
<volume>57</volume>
<fpage>21</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2016.03.022</pub-id>
<pub-id pub-id-type="pmid">27032568</pub-id>
</element-citation>
</ref>
<ref id="B71-life-10-00082">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Müller</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders</article-title>
<source/>Front. Psychiatry
          <year>2019</year>
<volume>10</volume>
<fpage>375</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00375</pub-id>
<pub-id pub-id-type="pmid">31214060</pub-id>
</element-citation>
</ref>
<ref id="B72-life-10-00082">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margaretten</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Julian</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yelin</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Depression in patients with rheumatoid arthritis: Description, causes and mechanisms</article-title>
<source/>Int. J. Clin. Rheumtol.
          <year>2011</year>
<volume>6</volume>
<fpage>617</fpage>
<lpage>623</lpage>
<pub-id pub-id-type="doi">10.2217/ijr.11.62</pub-id>
<pub-id pub-id-type="pmid">22211138</pub-id>
</element-citation>
</ref>
<ref id="B73-life-10-00082">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyring</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leonardi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lalla</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Woolley</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jahreis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zitnik</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial</article-title>
<source/>Lancet
          <year>2006</year>
<volume>367</volume>
<fpage>29</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(05)67763-X</pub-id>
<pub-id pub-id-type="pmid">16399150</pub-id>
</element-citation>
</ref>
<ref id="B74-life-10-00082">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammadinejad</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Arya</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Esfandbod</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kaviani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Najafi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kashani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zeinoddini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Emami</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Celecoxib versus diclofenac in mild to moderate depression management among breast cancer patients: A double-blind, placebo-controlled, randomized trial</article-title>
<source/>Ann. Pharmacother.
          <year>2015</year>
<volume>49</volume>
<fpage>953</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="doi">10.1177/1060028015592215</pub-id>
<pub-id pub-id-type="pmid">26139640</pub-id>
</element-citation>
</ref>
<ref id="B75-life-10-00082">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yirmiya</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Endotoxin produces a depressive-like episode in rats</article-title>
<source/>Brain Res.
          <year>1996</year>
<volume>711</volume>
<fpage>163</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/0006-8993(95)01415-2</pub-id>
<pub-id pub-id-type="pmid">8680860</pub-id>
</element-citation>
</ref>
<ref id="B76-life-10-00082">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anisman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Poulter</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Gandhi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Merali</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hayley</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Interferon-alpha effects are exaggerated when administered on a psychosocial stressor backdrop: Cytokine, corticosterone and brain monoamine variations</article-title>
<source/>J. Neuroimmunol.
          <year>2007</year>
<volume>186</volume>
<fpage>45</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.02.008</pub-id>
<pub-id pub-id-type="pmid">17428549</pub-id>
</element-citation>
</ref>
<ref id="B77-life-10-00082">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kubera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Leunis</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The gut-brain barrier in major depression: Intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression</article-title>
<source/>Neuro Endocrinol. Lett.
          <year>2008</year>
<volume>29</volume>
<fpage>117</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="pmid">18283240</pub-id>
</element-citation>
</ref>
<ref id="B78-life-10-00082">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borowski</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kokkinidis</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Merali</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Anisman</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Lipopolysaccharide, central in vivo biogenic amine variations, and anhedonia</article-title>
<source/>Neuroreport
          <year>1998</year>
<volume>9</volume>
<fpage>3797</fpage>
<lpage>3802</lpage>
<pub-id pub-id-type="doi">10.1097/00001756-199812010-00006</pub-id>
<pub-id pub-id-type="pmid">9875707</pub-id>
</element-citation>
</ref>
<ref id="B79-life-10-00082">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bluthe</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Michaud</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Poli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dantzer</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Role of IL-6 in cytokine-induced sickness behavior: A study with IL-6 deficient mice</article-title>
<source/>Physiol. Behav.
          <year>2000</year>
<volume>70</volume>
<fpage>367</fpage>
<lpage>373</lpage>
<pub-id pub-id-type="doi">10.1016/S0031-9384(00)00269-9</pub-id>
<pub-id pub-id-type="pmid">11006436</pub-id>
</element-citation>
</ref>
<ref id="B80-life-10-00082">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brietzke</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kauer-Sant’Anna</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder</article-title>
<source/>Brain Behav. Immun.
          <year>2009</year>
<volume>23</volume>
<fpage>1079</fpage>
<lpage>1082</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2009.04.008</pub-id>
<pub-id pub-id-type="pmid">19406226</pub-id>
</element-citation>
</ref>
<ref id="B81-life-10-00082">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldsmith</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Rapaport</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>B.J.</given-names>
</name>
</person-group>
<article-title>A meta-analysis of blood cytokine network alterations in psychiatric patients: Comparisons between schizophrenia, bipolar disorder and depression</article-title>
<source/>Mol. Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>1696</fpage>
<lpage>1709</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.3</pub-id>
<pub-id pub-id-type="pmid">26903267</pub-id>
</element-citation>
</ref>
<ref id="B82-life-10-00082">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felger</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Haroon</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Woolwine</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression</article-title>
<source/>Mol. Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>1358</fpage>
<lpage>1365</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.168</pub-id>
<pub-id pub-id-type="pmid">26552591</pub-id>
</element-citation>
</ref>
<ref id="B83-life-10-00082">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>A.H.</given-names>
</name>
</person-group>
<article-title>Beyond depression: The expanding role of inflammation in psychiatric disorders</article-title>
<source/>World Psychiatry
          <year>2020</year>
<volume>19</volume>
<fpage>108</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1002/wps.20723</pub-id>
<pub-id pub-id-type="pmid">31922681</pub-id>
</element-citation>
</ref>
<ref id="B84-life-10-00082">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chiriboga</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Pagoto</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Rosal</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Merriam</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Hébert</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Whited</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Ockene</surname>
<given-names>I.S.</given-names>
</name>
</person-group>
<article-title>Association between depression and c-reactive protein</article-title>
<source/>Cardiol. Res. Pract.
          <year>2010</year>
<volume>2011</volume>
<fpage>286509</fpage>
<pub-id pub-id-type="doi">10.4061/2011/286509</pub-id>
<pub-id pub-id-type="pmid">21234098</pub-id>
</element-citation>
</ref>
<ref id="B85-life-10-00082">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mondelli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Genetic contributions of inflammation to depression</article-title>
<source/>Neuropsychopharmacology
          <year>2017</year>
<volume>42</volume>
<fpage>81</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2016.169</pub-id>
<pub-id pub-id-type="pmid">27555379</pub-id>
</element-citation>
</ref>
<ref id="B86-life-10-00082">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McQuaid</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Gabrys</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>McInnis</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Anisman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Matheson</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Understanding the relation between early-life adversity and depression symptoms: The moderating role of sex and an interleukin-1beta gene variant</article-title>
<source/>Front. Psychiatry
          <year>2019</year>
<volume>10</volume>
<fpage>151</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00151</pub-id>
<pub-id pub-id-type="pmid">30967802</pub-id>
</element-citation>
</ref>
<ref id="B87-life-10-00082">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lezheiko</surname>
<given-names>T.V.</given-names>
</name>
<name>
<surname>Andryushchenko</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Korovaitseva</surname>
<given-names>G.I.</given-names>
</name>
<name>
<surname>Kondratiev</surname>
<given-names>N.V.</given-names>
</name>
<name>
<surname>Gabaeva</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Krikova</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Golimbet</surname>
<given-names>V.E.</given-names>
</name>
</person-group>
<article-title>A study on the association of genes for pro-inflammatory cytokines and depression</article-title>
<source/>Zhurnal Nevrol. Psikhiatr. S S Korsakova
          <year>2018</year>
<volume>118</volume>
<fpage>89</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="doi">10.17116/jnevro20181183189-93</pub-id>
<pub-id pub-id-type="pmid">29652312</pub-id>
</element-citation>
</ref>
<ref id="B88-life-10-00082">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yibulaiyin</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Depression is associated with CRP SNPs in patients with family history</article-title>
<source/>Transl. Neurosci.
          <year>2017</year>
<volume>8</volume>
<fpage>201</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1515/tnsci-2017-0027</pub-id>
<pub-id pub-id-type="pmid">29340226</pub-id>
</element-citation>
</ref>
<ref id="B89-life-10-00082">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michopoulos</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Powers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Ressler</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Jovanovic</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond</article-title>
<source/>Neuropsychopharmacology
          <year>2017</year>
<volume>42</volume>
<fpage>254</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2016.146</pub-id>
<pub-id pub-id-type="pmid">27510423</pub-id>
</element-citation>
</ref>
<ref id="B90-life-10-00082">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arteaga-Henriquez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Burger</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Weidinger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wijkhuijs</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Arolt</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Birkenhager</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Musil</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Drexhage</surname>
<given-names>H.A.</given-names>
</name>
</person-group>
<article-title>Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: A systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME consortium</article-title>
<source/>Front. Psychiatr.
          <year>2019</year>
<volume>10</volume>
<fpage>458</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00458</pub-id>
</element-citation>
</ref>
<ref id="B91-life-10-00082">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van Bockstaele</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Gastel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schotte</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Neels</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>DeMeester</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Scharpe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Janca</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The effects of psychological stress on leukocyte subset distribution in humans: Evidence of immune activation</article-title>
<source/>Neuropsychobiology
          <year>1999</year>
<volume>39</volume>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1159/000026552</pub-id>
<pub-id pub-id-type="pmid">9892853</pub-id>
</element-citation>
</ref>
<ref id="B92-life-10-00082">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lightman</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>The HPA axis in major depression: Classical theories and new developments</article-title>
<source/>Trends Neurosci.
          <year>2008</year>
<volume>31</volume>
<fpage>464</fpage>
<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2008.06.006</pub-id>
<pub-id pub-id-type="pmid">18675469</pub-id>
</element-citation>
</ref>
<ref id="B93-life-10-00082">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baumeister</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lightman</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>The HPA axis in the pathogenesis and treatment of depressive disorders: Integrating clinical and molecular findings</article-title>
<source/>Psychopathol. Rev.
          <year>2016</year>
<volume>3</volume>
<fpage>64</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="doi">10.5127/pr.034413</pub-id>
</element-citation>
</ref>
<ref id="B94-life-10-00082">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belvederi Murri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Prestia</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mondelli</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Pariante</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Patti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Olivieri</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Arzani</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Masotti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Respino</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Antonioli</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The HPA axis in bipolar disorder: Systematic review and meta-analysis</article-title>
<source/>Psychoneuroendocrinology
          <year>2016</year>
<volume>63</volume>
<fpage>327</fpage>
<lpage>342</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2015.10.014</pub-id>
<pub-id pub-id-type="pmid">26547798</pub-id>
</element-citation>
</ref>
<ref id="B95-life-10-00082">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herbert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goodyer</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Grossman</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Hastings</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>de Kloet</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Lightman</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Lupien</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Roozendaal</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Seckl</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Do corticosteroids damage the brain?</article-title>
<source/>J. Neuroendocrinol.
          <year>2006</year>
<volume>18</volume>
<fpage>393</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2826.2006.01429.x</pub-id>
<pub-id pub-id-type="pmid">16684130</pub-id>
</element-citation>
</ref>
<ref id="B96-life-10-00082">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Radom-Aizik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zaldivar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Glucocorticoid receptor expression on circulating leukocytes differs between healthy male and female adults</article-title>
<source/>J. Clin. Transl. Sci.
          <year>2017</year>
<volume>1</volume>
<fpage>108</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="doi">10.1017/cts.2016.20</pub-id>
<pub-id pub-id-type="pmid">28649452</pub-id>
</element-citation>
</ref>
<ref id="B97-life-10-00082">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>The glucocorticoid receptor: Part of the solution or part of the problem?</article-title>
<source/>J. Psychopharmacol.
          <year>2006</year>
<volume>20</volume>
<fpage>79</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1177/1359786806066063</pub-id>
<pub-id pub-id-type="pmid">16785275</pub-id>
</element-citation>
</ref>
<ref id="B98-life-10-00082">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nemeroff</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Vale</surname>
<given-names>W.W.</given-names>
</name>
</person-group>
<article-title>The neurobiology of depression: Inroads to treatment and new drug discovery</article-title>
<source/>J. Clin. Psychiatry
          <year>2005</year>
<volume>66</volume>
<fpage>5</fpage>
<lpage>13</lpage>
</element-citation>
</ref>
<ref id="B99-life-10-00082">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brites</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fernandes</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neuroinflammation and depression: Microglia activation, extracellular microvesicles and microRNA dysregulation</article-title>
<source/>Front. Cell. Neurosci.
          <year>2015</year>
<volume>9</volume>
<fpage>476</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2015.00476</pub-id>
<pub-id pub-id-type="pmid">26733805</pub-id>
</element-citation>
</ref>
<ref id="B100-life-10-00082">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palego</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Betti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giannaccini</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Tryptophan biochemistry: Structural, nutritional, metabolic, and medical aspects in humans</article-title>
<source/>J. Amino Acids.
          <year>2016</year>
<volume>2016</volume>
<fpage>8952520</fpage>
<pub-id pub-id-type="doi">10.1155/2016/8952520</pub-id>
<pub-id pub-id-type="pmid">26881063</pub-id>
</element-citation>
</ref>
<ref id="B101-life-10-00082">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tafet</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>The links between stress and depression: Psychoneuroendocrinological, genetic, and environmental interactions</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci.
          <year>2016</year>
<volume>28</volume>
<fpage>77</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1176/appi.neuropsych.15030053</pub-id>
<pub-id pub-id-type="pmid">26548654</pub-id>
</element-citation>
</ref>
<ref id="B102-life-10-00082">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Melo</surname>
<given-names>L.G.P.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>S.O.V.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>H.O.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Galecki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Shared metabolic and immune-inflammatory, oxidative and nitrosative stress pathways in the metabolic syndrome and mood disorders</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2017</year>
<volume>78</volume>
<fpage>34</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.04.027</pub-id>
<pub-id pub-id-type="pmid">28438472</pub-id>
</element-citation>
</ref>
<ref id="B103-life-10-00082">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solleiro-Villavicencio</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rivas-Arancibia</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4(+)T cells in neurodegenerative diseases</article-title>
<source/>Front. Cell. Neurosci.
          <year>2018</year>
<volume>12</volume>
<fpage>114</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2018.00114</pub-id>
<pub-id pub-id-type="pmid">29755324</pub-id>
</element-citation>
</ref>
<ref id="B104-life-10-00082">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siwek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sowa-Kucma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dudek</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Styczen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Szewczyk</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kotarska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Misztakk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pilc</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wolak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nowak</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Oxidative stress markers in affective disorders</article-title>
<source/>Pharmacol. Rep.
          <year>2013</year>
<volume>65</volume>
<fpage>1558</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1016/S1734-1140(13)71517-2</pub-id>
<pub-id pub-id-type="pmid">24553004</pub-id>
</element-citation>
</ref>
<ref id="B105-life-10-00082">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guu</surname>
<given-names>T.W.</given-names>
</name>
<name>
<surname>Mischoulon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sarris</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hibbeln</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McNamara</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Hamazaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Matsuoka</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Belmaker</surname>
<given-names>R.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>International society for nutritional psychiatry research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder</article-title>
<source/>Psychother. Psychosom.
          <year>2019</year>
<volume>88</volume>
<fpage>263</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1159/000502652</pub-id>
<pub-id pub-id-type="pmid">31480057</pub-id>
</element-citation>
</ref>
<ref id="B106-life-10-00082">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Firth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Teasdale</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Allott</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Siskind</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Marx</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cotter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Veronese</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schuch</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Solmi</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The efficacy and safety of nutrient supplements in the treatment of mental disorders: A meta-review of meta-analyses of randomized controlled trials</article-title>
<source/>World Psychiatry
          <year>2019</year>
<volume>18</volume>
<fpage>308</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="doi">10.1002/wps.20672</pub-id>
<pub-id pub-id-type="pmid">31496103</pub-id>
</element-citation>
</ref>
<ref id="B107-life-10-00082">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watkins</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pomper</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Glia and immune cell signaling in bipolar disorder: Insights from neuropharmacology and molecular imaging to clinical application</article-title>
<source/>Transl. Psychiatry
          <year>2014</year>
<volume>4</volume>
<fpage>e350</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2013.119</pub-id>
<pub-id pub-id-type="pmid">24448212</pub-id>
</element-citation>
</ref>
<ref id="B108-life-10-00082">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Czarny</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wigner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Galecki</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sliwinski</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>The interplay between inflammation, oxidative stress, DNA damage, DNA repair and mitochondrial dysfunction in depression</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2018</year>
<volume>80</volume>
<fpage>309</fpage>
<lpage>321</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.06.036</pub-id>
<pub-id pub-id-type="pmid">28669580</pub-id>
</element-citation>
</ref>
<ref id="B109-life-10-00082">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Norhaizan</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Liew</surname>
<given-names>W.-P.-P.</given-names>
</name>
<name>
<surname>Sulaiman Rahman</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Antioxidant and oxidative stress: A mutual interplay in age-related diseases</article-title>
<source/>Front. Pharmacol.
          <year>2018</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.3389/fphar.2018.01162</pub-id>
</element-citation>
</ref>
<ref id="B110-life-10-00082">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maurya</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Noto</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rizzo</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Rios</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Nunes</surname>
<given-names>S.O.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Sethi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zeni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mansur</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2016</year>
<volume>65</volume>
<fpage>134</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2015.08.016</pub-id>
<pub-id pub-id-type="pmid">26348786</pub-id>
</element-citation>
</ref>
<ref id="B111-life-10-00082">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liguori</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Curcio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bulli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aran</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Della-Morte</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gargiulo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Testa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cacciatore</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bonaduce</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxidative stress, aging, and diseases</article-title>
<source/>Clin. Interv. Aging
          <year>2018</year>
<volume>13</volume>
<fpage>757</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S158513</pub-id>
<pub-id pub-id-type="pmid">29731617</pub-id>
</element-citation>
</ref>
<ref id="B112-life-10-00082">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sosa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Moline</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Somoza</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Paciucci</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kondoh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>ME</surname>
<given-names>L.L.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and cancer: An overview</article-title>
<source/>Ageing Res. Rev.
          <year>2013</year>
<volume>12</volume>
<fpage>376</fpage>
<lpage>390</lpage>
<pub-id pub-id-type="doi">10.1016/j.arr.2012.10.004</pub-id>
<pub-id pub-id-type="pmid">23123177</pub-id>
</element-citation>
</ref>
<ref id="B113-life-10-00082">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhalla</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Temsah</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Netticadan</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Role of oxidative stress in cardiovascular diseases</article-title>
<source/>J. Hypertens.
          <year>2000</year>
<volume>18</volume>
<fpage>655</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="doi">10.1097/00004872-200018060-00002</pub-id>
<pub-id pub-id-type="pmid">10872549</pub-id>
</element-citation>
</ref>
<ref id="B114-life-10-00082">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uttara</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Zamboni</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mahajan</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options</article-title>
<source/>Curr. Neuropharmacol.
          <year>2009</year>
<volume>7</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.2174/157015909787602823</pub-id>
<pub-id pub-id-type="pmid">19721819</pub-id>
</element-citation>
</ref>
<ref id="B115-life-10-00082">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A.I.</given-names>
</name>
</person-group>
<article-title>Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2008</year>
<volume>11</volume>
<fpage>851</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145707008401</pub-id>
<pub-id pub-id-type="pmid">18205981</pub-id>
</element-citation>
</ref>
<ref id="B116-life-10-00082">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsaluchidu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cocchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tonello</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Puri</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Fatty acids and oxidative stress in psychiatric disorders</article-title>
<source/>BMC Psychiatry
          <year>2008</year>
<volume>8</volume>
<elocation-id>S5</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-244X-8-S1-S5</pub-id>
<pub-id pub-id-type="pmid">18433515</pub-id>
</element-citation>
</ref>
<ref id="B117-life-10-00082">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nunomura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tamaoki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Motohashi</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Role of oxidative stress in the pathophysiology of neuropsychiatric disorders</article-title>
<source/>Seishin Shinkeigaku Zasshi
          <year>2014</year>
<volume>116</volume>
<fpage>842</fpage>
<lpage>858</lpage>
<pub-id pub-id-type="pmid">25672211</pub-id>
</element-citation>
</ref>
<ref id="B118-life-10-00082">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michel</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Pulschen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thome</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>The role of oxidative stress in depressive disorders</article-title>
<source/>Curr. Pharm. Des.
          <year>2012</year>
<volume>18</volume>
<fpage>5890</fpage>
<lpage>5899</lpage>
<pub-id pub-id-type="doi">10.2174/138161212803523554</pub-id>
<pub-id pub-id-type="pmid">22681168</pub-id>
</element-citation>
</ref>
<ref id="B119-life-10-00082">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajpai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Srivastava</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Oxidative stress and major depression</article-title>
<source/>J. Clin. Diagn. Res.
          <year>2014</year>
<volume>8</volume>
<fpage>CC04-7</fpage>
<pub-id pub-id-type="doi">10.7860/JCDR/2014/10258.5292</pub-id>
</element-citation>
</ref>
<ref id="B120-life-10-00082">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>A meta-analysis of oxidative stress markers in depression</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0138904</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0138904</pub-id>
<pub-id pub-id-type="pmid">26445247</pub-id>
</element-citation>
</ref>
<ref id="B121-life-10-00082">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vavakova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Durackova</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Trebaticka</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Markers of oxidative stress and neuroprogression in depression disorder</article-title>
<source/>Oxid. Med. Cell Longev.
          <year>2015</year>
<volume>2015</volume>
<fpage>898393</fpage>
<pub-id pub-id-type="doi">10.1155/2015/898393</pub-id>
<pub-id pub-id-type="pmid">26078821</pub-id>
</element-citation>
</ref>
<ref id="B122-life-10-00082">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ozcan</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Gulec</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ozerol</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Polat</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Akyol</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Antioxidant enzyme activities and oxidative stress in affective disorders</article-title>
<source/>Int. Clin. Psychopharmacol.
          <year>2004</year>
<volume>19</volume>
<fpage>89</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.1097/00004850-200403000-00006</pub-id>
<pub-id pub-id-type="pmid">15076017</pub-id>
</element-citation>
</ref>
<ref id="B123-life-10-00082">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Allen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Romay-Tallon</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brymer</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Caruncho</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Kalynchuk</surname>
<given-names>L.E.</given-names>
</name>
</person-group>
<article-title>Mitochondria and mood: Mitochondrial dysfunction as a key player in the manifestation of depression</article-title>
<source/>Front. Neurosci.
          <year>2018</year>
<volume>12</volume>
<fpage>386</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2018.00386</pub-id>
<pub-id pub-id-type="pmid">29928190</pub-id>
</element-citation>
</ref>
<ref id="B124-life-10-00082">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Del Grande</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Musetti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Turri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cirronis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pergentini</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Corsi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dell’Osso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Corsini</surname>
<given-names>G.U.</given-names>
</name>
</person-group>
<article-title>Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium</article-title>
<source/>Psychiatry Res.
          <year>2015</year>
<volume>225</volume>
<fpage>604</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2014.11.038</pub-id>
<pub-id pub-id-type="pmid">25547850</pub-id>
</element-citation>
</ref>
<ref id="B125-life-10-00082">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Black</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Bot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Snieder</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Penninx</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Uric acid in major depressive and anxiety disorders</article-title>
<source/>J. Affect. Disord.
          <year>2018</year>
<volume>225</volume>
<fpage>684</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2017.09.003</pub-id>
<pub-id pub-id-type="pmid">28917195</pub-id>
</element-citation>
</ref>
<ref id="B126-life-10-00082">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maiuolo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Oppedisano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gratteri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Muscoli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mollace</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Regulation of uric acid metabolism and excretion</article-title>
<source/>Int. J. Cardiol.
          <year>2016</year>
<volume>213</volume>
<fpage>8</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2015.08.109</pub-id>
<pub-id pub-id-type="pmid">26316329</pub-id>
</element-citation>
</ref>
<ref id="B127-life-10-00082">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malewska-Kasprzak</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Permoda-Osip</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rybakowski</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Disturbances of purinergic system in affective disorders and schizophrenia</article-title>
<source/>Psychiatr. Pol.
          <year>2019</year>
<volume>53</volume>
<fpage>577</fpage>
<lpage>587</lpage>
<pub-id pub-id-type="doi">10.12740/PP/97335</pub-id>
<pub-id pub-id-type="pmid">31522198</pub-id>
</element-citation>
</ref>
<ref id="B128-life-10-00082">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ortiz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Machado-Vieira</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Purinergic system dysfunction in mood disorders: A key target for developing improved therapeutics</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2015</year>
<volume>57</volume>
<fpage>117</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.10.016</pub-id>
<pub-id pub-id-type="pmid">25445063</pub-id>
</element-citation>
</ref>
<ref id="B129-life-10-00082">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krugel</surname>
<given-names>U.</given-names>
</name>
</person-group>
<article-title>Purinergic receptors in psychiatric disorders</article-title>
<source/>Neuropharmacology
          <year>2016</year>
<volume>104</volume>
<fpage>212</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.032</pub-id>
<pub-id pub-id-type="pmid">26518371</pub-id>
</element-citation>
</ref>
<ref id="B130-life-10-00082">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hille</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Basu</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The mononuclear molybdenum enzymes</article-title>
<source/>Chem. Rev.
          <year>2014</year>
<volume>114</volume>
<fpage>3963</fpage>
<lpage>4038</lpage>
<pub-id pub-id-type="doi">10.1021/cr400443z</pub-id>
<pub-id pub-id-type="pmid">24467397</pub-id>
</element-citation>
</ref>
<ref id="B131-life-10-00082">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ames</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Cathcart</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schwiers</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hochstein</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1981</year>
<volume>78</volume>
<fpage>6858</fpage>
<lpage>6862</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.78.11.6858</pub-id>
<pub-id pub-id-type="pmid">6947260</pub-id>
</element-citation>
</ref>
<ref id="B132-life-10-00082">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nieto</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Iribarren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Comstock</surname>
<given-names>G.W.</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Uric acid and serum antioxidant capacity: A reaction to atherosclerosis?</article-title>
<source/>Atherosclerosis
          <year>2000</year>
<volume>148</volume>
<fpage>131</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1016/S0021-9150(99)00214-2</pub-id>
<pub-id pub-id-type="pmid">10580179</pub-id>
</element-citation>
</ref>
<ref id="B133-life-10-00082">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sautin</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Uric acid: The oxidant-antioxidant paradox</article-title>
<source/>Nucleosides Nucleotides Nucleic Acids
          <year>2008</year>
<volume>27</volume>
<fpage>608</fpage>
<lpage>619</lpage>
<pub-id pub-id-type="doi">10.1080/15257770802138558</pub-id>
<pub-id pub-id-type="pmid">18600514</pub-id>
</element-citation>
</ref>
<ref id="B134-life-10-00082">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbracchio</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Burnstock</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Verkhratsky</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zimmermann</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Purinergic signalling in the nervous system: An overview</article-title>
<source/>Trends Neurosci.
          <year>2009</year>
<volume>32</volume>
<fpage>19</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1016/j.tins.2008.10.001</pub-id>
<pub-id pub-id-type="pmid">19008000</pub-id>
</element-citation>
</ref>
<ref id="B135-life-10-00082">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cieslak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wojtczak</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Role of purinergic receptors in the Alzheimer’s disease</article-title>
<source/>Purinergic Signal.
          <year>2018</year>
<volume>14</volume>
<fpage>331</fpage>
<lpage>344</lpage>
<pub-id pub-id-type="doi">10.1007/s11302-018-9629-0</pub-id>
<pub-id pub-id-type="pmid">30362042</pub-id>
</element-citation>
</ref>
<ref id="B136-life-10-00082">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira-Giacomelli</surname>
<given-names>Á.</given-names>
</name>
<name>
<surname>Naaldijk</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sardá-Arroyo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>M.C.B.</given-names>
</name>
<name>
<surname>Corrêa-Velloso</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pillat</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>H.D.N.</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Purinergic receptors in neurological diseases with motor symptoms: Targets for therapy</article-title>
<source/>Front. Pharmacol.
          <year>2018</year>
<volume>9</volume>
<fpage>325</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2018.00325</pub-id>
<pub-id pub-id-type="pmid">29692728</pub-id>
</element-citation>
</ref>
<ref id="B137-life-10-00082">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnstock</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Purinergic signalling and neurological diseases: An update</article-title>
<source/>CNS Neurol. Disord. Drug Targets
          <year>2017</year>
<volume>16</volume>
<fpage>257</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.2174/1871527315666160922104848</pub-id>
<pub-id pub-id-type="pmid">27658510</pub-id>
</element-citation>
</ref>
<ref id="B138-life-10-00082">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cieślak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Czarnecka</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roszek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Komoszyński</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The role of purinergic signaling in the etiology of migraine and novel antimigraine treatment</article-title>
<source/>Purinergic Signal.
          <year>2015</year>
<volume>11</volume>
<fpage>307</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1007/s11302-015-9453-8</pub-id>
<pub-id pub-id-type="pmid">25957584</pub-id>
</element-citation>
</ref>
<ref id="B139-life-10-00082">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matute</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cavaliere</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Neuroglial interactions mediated by purinergic signalling in the pathophysiology of CNS disorders</article-title>
<source/>Semin. Cell Dev. Biol.
          <year>2011</year>
<volume>22</volume>
<fpage>252</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1016/j.semcdb.2011.02.011</pub-id>
<pub-id pub-id-type="pmid">21320622</pub-id>
</element-citation>
</ref>
<ref id="B140-life-10-00082">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schretlen</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Puig</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Nyhan</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Jinnah</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Behavioral aspects of Lesch-Nyhan disease and its variants</article-title>
<source/>Dev. Med. Child Neurol.
          <year>2005</year>
<volume>47</volume>
<fpage>673</fpage>
<lpage>677</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162205001374</pub-id>
<pub-id pub-id-type="pmid">16174310</pub-id>
</element-citation>
</ref>
<ref id="B141-life-10-00082">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kraepelin</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Manic depressive insanity and paranoia</article-title>
<source/>J. Nerv. Ment. Dis.
          <year>1921</year>
<volume>53</volume>
<fpage>350</fpage>
<pub-id pub-id-type="doi">10.1097/00005053-192104000-00057</pub-id>
</element-citation>
</ref>
<ref id="B142-life-10-00082">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brooks</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Linn</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Disney</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Serotonin, folic acid, and uric acid metabolism in the diagnosis of neuropsychiatric disorders</article-title>
<source/>Biol. Psychiatry
          <year>1978</year>
<volume>13</volume>
<fpage>671</fpage>
<lpage>684</lpage>
<pub-id pub-id-type="pmid">737255</pub-id>
</element-citation>
</ref>
<ref id="B143-life-10-00082">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Berardis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Conti</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Campanella</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Di Giuseppe</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Valchera</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tancredi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Serroni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pizzorno</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Fulcheri</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder</article-title>
<source/>J. Biol. Regul. Homeost. Agents
          <year>2008</year>
<volume>22</volume>
<fpage>195</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="pmid">18842173</pub-id>
</element-citation>
</ref>
<ref id="B144-life-10-00082">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvadore</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Viale</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Luckenbaugh</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Zanatto</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Portela</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>D.O.</given-names>
</name>
<name>
<surname>Zarate</surname>
<given-names>C.A.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Machado-Vieira</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Increased uric acid levels in drug-naive subjects with bipolar disorder during a first manic episode</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2010</year>
<volume>34</volume>
<fpage>819</fpage>
<lpage>821</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2010.02.027</pub-id>
<pub-id pub-id-type="pmid">20206224</pub-id>
</element-citation>
</ref>
<ref id="B145-life-10-00082">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machado-Vieira</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Purinergic system in the treatment of bipolar disorder: Uric acid levels as a screening test in mania</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2012</year>
<volume>32</volume>
<fpage>735</fpage>
<lpage>736</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e318268391d</pub-id>
<pub-id pub-id-type="pmid">22926622</pub-id>
</element-citation>
</ref>
<ref id="B146-life-10-00082">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kesebir</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Suner</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Yaylaci</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Bayrak</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turan</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Increased uric acid levels in bipolar disorder: Is it trait or state?</article-title>
<source/>J. Biol. Regul. Homeost. Agents
          <year>2013</year>
<volume>27</volume>
<fpage>981</fpage>
<lpage>988</lpage>
<pub-id pub-id-type="pmid">24382179</pub-id>
</element-citation>
</ref>
<ref id="B147-life-10-00082">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Serum uric acid levels and the clinical characteristics of depression</article-title>
<source/>Clin. Biochem.
          <year>2012</year>
<volume>45</volume>
<fpage>49</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2011.10.010</pub-id>
<pub-id pub-id-type="pmid">22040815</pub-id>
</element-citation>
</ref>
<ref id="B148-life-10-00082">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anumonye</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reading</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Knight</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ashcroft</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>Uric-acid metabolism in manic-depressive illness and during lithium therapy</article-title>
<source/>Lancet
          <year>1968</year>
<volume>1</volume>
<fpage>1290</fpage>
<lpage>1293</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(68)92300-3</pub-id>
<pub-id pub-id-type="pmid">4172145</pub-id>
</element-citation>
</ref>
<ref id="B149-life-10-00082">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Mallakh</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Jefferson</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Prethymoleptic use of lithium</article-title>
<source/>Am. J. Psychiatry
          <year>1999</year>
<volume>156</volume>
<fpage>129</fpage>
<pub-id pub-id-type="doi">10.1176/ajp.156.1.129</pub-id>
<pub-id pub-id-type="pmid">9892308</pub-id>
</element-citation>
</ref>
<ref id="B150-life-10-00082">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ring</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>E.H.</given-names>
</name>
</person-group>
<article-title>Plasma uric acid in patients receiving anticonvulsant monotherapy</article-title>
<source/>Epilepsy Res.
          <year>1991</year>
<volume>8</volume>
<fpage>241</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1016/0920-1211(91)90070-V</pub-id>
<pub-id pub-id-type="pmid">1868823</pub-id>
</element-citation>
</ref>
<ref id="B151-life-10-00082">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karve</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Jagtiani</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Chitnis</surname>
<given-names>K.A.</given-names>
</name>
</person-group>
<article-title>Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice</article-title>
<source/>Indian J. Pharmacol.
          <year>2013</year>
<volume>45</volume>
<fpage>244</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.4103/0253-7613.111922</pub-id>
<pub-id pub-id-type="pmid">23833366</pub-id>
</element-citation>
</ref>
<ref id="B152-life-10-00082">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erb</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ajit</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Weisman</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>P2Y receptors in Alzheimer’s disease</article-title>
<source/>Biol. Cell
          <year>2015</year>
<volume>107</volume>
<fpage>1</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1111/boc.201400043</pub-id>
<pub-id pub-id-type="pmid">25179475</pub-id>
</element-citation>
</ref>
<ref id="B153-life-10-00082">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wardas</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Neuroprotective role of adenosine in the CNS</article-title>
<source/>Pol. J. Pharmacol.
          <year>2002</year>
<volume>54</volume>
<fpage>313</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="pmid">12523485</pub-id>
</element-citation>
</ref>
<ref id="B154-life-10-00082">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kellett</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>N.M.</given-names>
</name>
</person-group>
<article-title>The role of tissue non-specific alkaline phosphatase (TNAP) in neurodegenerative diseases: Alzheimer’s disease in the focus</article-title>
<source/>Subcell. Biochem.
          <year>2015</year>
<volume>76</volume>
<fpage>363</fpage>
<lpage>374</lpage>
<pub-id pub-id-type="doi">10.1007/978-94-017-7197-9_17</pub-id>
<pub-id pub-id-type="pmid">26219720</pub-id>
</element-citation>
</ref>
<ref id="B155-life-10-00082">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnstock</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>P2X ion channel receptors and inflammation</article-title>
<source/>Purinergic Signal.
          <year>2016</year>
<volume>12</volume>
<fpage>59</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1007/s11302-015-9493-0</pub-id>
<pub-id pub-id-type="pmid">26739702</pub-id>
</element-citation>
</ref>
<ref id="B156-life-10-00082">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansoleaga</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jove</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schluter</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Garcia-Esparcia</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Moreno</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pujol</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pamplona</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Portero-Otin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Deregulation of purine metabolism in Alzheimer’s disease</article-title>
<source/>Neurobiol. Aging
          <year>2015</year>
<volume>36</volume>
<fpage>68</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.08.004</pub-id>
<pub-id pub-id-type="pmid">25311278</pub-id>
</element-citation>
</ref>
<ref id="B157-life-10-00082">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castellani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hirai</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aliev</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Drew</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Nunomura</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cash</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Obrenovich</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Role of mitochondrial dysfunction in Alzheimer’s disease</article-title>
<source/>J. Neurosci. Res.
          <year>2002</year>
<volume>70</volume>
<fpage>357</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.10389</pub-id>
<pub-id pub-id-type="pmid">12391597</pub-id>
</element-citation>
</ref>
<ref id="B158-life-10-00082">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Procaccio</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bris</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chao de la Barca</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Oca</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Chevrollier</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Amati-Bonneau</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bonneau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Reynier</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Perspectives of drug-based neuroprotection targeting mitochondria</article-title>
<source/>Rev. Neurol.
          <year>2014</year>
<volume>170</volume>
<fpage>390</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurol.2014.03.005</pub-id>
<pub-id pub-id-type="pmid">24792485</pub-id>
</element-citation>
</ref>
<ref id="B159-life-10-00082">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camandola</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Aberrant subcellular neuronal calcium regulation in aging and Alzheimer’s disease</article-title>
<source/>Biochim. Biophys. Acta
          <year>2011</year>
<volume>1813</volume>
<fpage>965</fpage>
<lpage>973</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbamcr.2010.10.005</pub-id>
<pub-id pub-id-type="pmid">20950656</pub-id>
</element-citation>
</ref>
<ref id="B160-life-10-00082">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Lores Arnaiz</surname>
<given-names>G.R.</given-names>
</name>
<name>
<surname>Ordieres</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Brain Na<sup>+</sup>, K<sup>+</sup>-ATPase activity in aging and disease</article-title>
<source/>Int. J. Biomed. Sci.
          <year>2014</year>
<volume>10</volume>
<fpage>85</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="pmid">25018677</pub-id>
</element-citation>
</ref>
<ref id="B161-life-10-00082">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bishnoi</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Clinical potential of allopurinol in the treatment of bipolar disorder</article-title>
<source/>Indian J. Psychol.Med.
          <year>2014</year>
<volume>36</volume>
<fpage>218</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.4103/0253-7176.131008</pub-id>
</element-citation>
</ref>
<ref id="B162-life-10-00082">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dwivedi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor: Role in depression and suicide</article-title>
<source/>Neuropsychiatr. Dis. Treat.
          <year>2009</year>
<volume>5</volume>
<fpage>433</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S5700</pub-id>
<pub-id pub-id-type="pmid">19721723</pub-id>
</element-citation>
</ref>
<ref id="B163-life-10-00082">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.Y.</given-names>
</name>
</person-group>
<article-title>The role of BDNF in depression on the basis of its location in the neural circuitry</article-title>
<source/>Acta Pharmacol. Sin.
          <year>2011</year>
<volume>32</volume>
<fpage>3</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="doi">10.1038/aps.2010.184</pub-id>
<pub-id pub-id-type="pmid">21131999</pub-id>
</element-citation>
</ref>
<ref id="B164-life-10-00082">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.K.</given-names>
</name>
</person-group>
<article-title>The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment</article-title>
<source/>Psychiatry Investig.
          <year>2010</year>
<volume>7</volume>
<fpage>231</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.4306/pi.2010.7.4.231</pub-id>
<pub-id pub-id-type="pmid">21253405</pub-id>
</element-citation>
</ref>
<ref id="B165-life-10-00082">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions</article-title>
<source/>Psychiatry Clin. Neurosci.
          <year>2010</year>
<volume>64</volume>
<fpage>341</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1819.2010.02113.x</pub-id>
<pub-id pub-id-type="pmid">20653908</pub-id>
</element-citation>
</ref>
<ref id="B166-life-10-00082">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castren</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Neurotrophins and psychiatric disorders</article-title>
<source/>Handb. Exp. Pharmacol.
          <year>2014</year>
<volume>220</volume>
<fpage>461</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-642-45106-5_17</pub-id>
<pub-id pub-id-type="pmid">24668483</pub-id>
</element-citation>
</ref>
<ref id="B167-life-10-00082">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bocchio-Chiavetto</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bagnardi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zanardini</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Molteni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nielsen</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Placentino</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giovannini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rillosi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ventriglia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>M.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serum and plasma BDNF levels in major depression: A replication study and meta-analyses</article-title>
<source/>World J. Biol. Psychiatry
          <year>2010</year>
<volume>11</volume>
<fpage>763</fpage>
<lpage>773</lpage>
<pub-id pub-id-type="doi">10.3109/15622971003611319</pub-id>
<pub-id pub-id-type="pmid">20334574</pub-id>
</element-citation>
</ref>
<ref id="B168-life-10-00082">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karege</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bondolfi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gervasoni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schwald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aubry</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Bertschy</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity</article-title>
<source/>Biol. Psychiatry
          <year>2005</year>
<volume>57</volume>
<fpage>1068</fpage>
<lpage>1072</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.01.008</pub-id>
<pub-id pub-id-type="pmid">15860348</pub-id>
</element-citation>
</ref>
<ref id="B169-life-10-00082">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gervasoni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Aubry</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Bondolfi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Osiek</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schwald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bertschy</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Karege</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Partial normalization of serum brain-derived neurotrophic factor in remitted patients after a major depressive episode</article-title>
<source/>Neuropsychobiology
          <year>2005</year>
<volume>51</volume>
<fpage>234</fpage>
<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1159/000085725</pub-id>
<pub-id pub-id-type="pmid">15897674</pub-id>
</element-citation>
</ref>
<ref id="B170-life-10-00082">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molendijk</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Bus</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Spinhoven</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Penninx</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Kenis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Prickaerts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Voshaar</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Elzinga</surname>
<given-names>B.M.</given-names>
</name>
</person-group>
<article-title>Serum levels of brain-derived neurotrophic factor in major depressive disorder: State-trait issues, clinical features and pharmacological treatment</article-title>
<source/>Mol. Psychiatry
          <year>2011</year>
<volume>16</volume>
<fpage>1088</fpage>
<lpage>1095</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2010.98</pub-id>
<pub-id pub-id-type="pmid">20856249</pub-id>
</element-citation>
</ref>
<ref id="B171-life-10-00082">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sanacora</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications</article-title>
<source/>Biol. Psychiatry
          <year>2008</year>
<volume>64</volume>
<fpage>527</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.05.005</pub-id>
<pub-id pub-id-type="pmid">18571629</pub-id>
</element-citation>
</ref>
<ref id="B172-life-10-00082">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>C.K.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>P.C.</given-names>
</name>
</person-group>
<article-title>Decreased plasma brain-derived neurotrophic factor levels in institutionalized elderly with depressive disorder</article-title>
<source/>J. Am. Med. Dir. Assoc.
          <year>2012</year>
<volume>13</volume>
<fpage>434</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1016/j.jamda.2011.08.006</pub-id>
<pub-id pub-id-type="pmid">21944169</pub-id>
</element-citation>
</ref>
<ref id="B173-life-10-00082">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diniz</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Talib</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Mendonca</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Gattaz</surname>
<given-names>W.F.</given-names>
</name>
<name>
<surname>Forlenza</surname>
<given-names>O.V.</given-names>
</name>
</person-group>
<article-title>Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression</article-title>
<source/>World J. Biol. Psychiatry
          <year>2010</year>
<volume>11</volume>
<fpage>550</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.3109/15622970903544620</pub-id>
<pub-id pub-id-type="pmid">20109109</pub-id>
</element-citation>
</ref>
<ref id="B174-life-10-00082">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Plasma BDNF and tPA are associated with late-onset geriatric depression</article-title>
<source/>Psychiatry Clin. Neurosci.
          <year>2010</year>
<volume>64</volume>
<fpage>249</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1819.2010.02074.x</pub-id>
<pub-id pub-id-type="pmid">20602725</pub-id>
</element-citation>
</ref>
<ref id="B175-life-10-00082">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karege</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perret</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bondolfi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Schwald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bertschy</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aubry</surname>
<given-names>J.M.</given-names>
</name>
</person-group>
<article-title>Decreased serum brain-derived neurotrophic factor levels in major depressed patients</article-title>
<source/>Psychiatry Res.
          <year>2002</year>
<volume>109</volume>
<fpage>143</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-1781(02)00005-7</pub-id>
<pub-id pub-id-type="pmid">11927139</pub-id>
</element-citation>
</ref>
<ref id="B176-life-10-00082">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serra-Millas</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation?</article-title>
<source/>World J. Psychiatry
          <year>2016</year>
<volume>6</volume>
<fpage>84</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.5498/wjp.v6.i1.84</pub-id>
<pub-id pub-id-type="pmid">27014600</pub-id>
</element-citation>
</ref>
<ref id="B177-life-10-00082">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knorr</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Sondergaard</surname>
<given-names>M.H.G.</given-names>
</name>
<name>
<surname>Koefoed</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jorgensen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Faurholt-Jepsen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vinberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kessing</surname>
<given-names>L.V.</given-names>
</name>
</person-group>
<article-title>Increased blood BDNF in healthy individuals with a family history of depression</article-title>
<source/>Psychiatry Res.
          <year>2017</year>
<volume>256</volume>
<fpage>176</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2017.06.057</pub-id>
<pub-id pub-id-type="pmid">28645077</pub-id>
</element-citation>
</ref>
<ref id="B178-life-10-00082">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccinni</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Veltri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Costanzo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vanelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Franceschini</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moroni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Domenici</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Origlia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Marazziti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Akiskal</surname>
<given-names>H.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased plasma levels of brain-derived neurotrophic factor (BDNF) during mixed episodes of bipolar disorder</article-title>
<source/>J. Affect. Disord.
          <year>2015</year>
<volume>171</volume>
<fpage>167</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2014.08.058</pub-id>
<pub-id pub-id-type="pmid">25305432</pub-id>
</element-citation>
</ref>
<ref id="B179-life-10-00082">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freire</surname>
<given-names>T.F.</given-names>
</name>
<name>
<surname>Fleck</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>da Rocha</surname>
<given-names>N.S.</given-names>
</name>
</person-group>
<article-title>Remission of depression following electroconvulsive therapy (ECT) is associated with higher levels of brain-derived neurotrophic factor (BDNF)</article-title>
<source/>Brain Res. Bull.
          <year>2016</year>
<volume>121</volume>
<fpage>263</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresbull.2016.02.013</pub-id>
<pub-id pub-id-type="pmid">26892396</pub-id>
</element-citation>
</ref>
<ref id="B180-life-10-00082">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Koike</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Komatsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kumakiri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nakazato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Watanabe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shinoda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Okada</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants</article-title>
<source/>Biol. Psychiatry
          <year>2003</year>
<volume>54</volume>
<fpage>70</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(03)00181-1</pub-id>
<pub-id pub-id-type="pmid">12842310</pub-id>
</element-citation>
</ref>
<ref id="B181-life-10-00082">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimura</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ikenouchi-Sugita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Umene-Nakano</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Katsuki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Atake</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor (BDNF) and mood disorder</article-title>
<source/>Nihon Shinkei Seishin Yakurigaku Zasshi
          <year>2010</year>
<volume>30</volume>
<fpage>181</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="pmid">21226313</pub-id>
</element-citation>
</ref>
<ref id="B182-life-10-00082">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nishino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Numata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study</article-title>
<source/>PLoS ONE
          <year>2012</year>
<volume>7</volume>
<elocation-id>e39212</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0039212</pub-id>
<pub-id pub-id-type="pmid">22761741</pub-id>
</element-citation>
</ref>
<ref id="B183-life-10-00082">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitriadis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>van den Brink</surname>
<given-names>R.H.S.</given-names>
</name>
<name>
<surname>Comijs</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Oude Voshaar</surname>
<given-names>R.C.</given-names>
</name>
</person-group>
<article-title>Prognostic effect of serum BDNF levels in late-life depression: Moderated by childhood trauma and SSRI usage?</article-title>
<source/>Psychoneuroendocrinology
          <year>2019</year>
<volume>103</volume>
<fpage>276</fpage>
<lpage>283</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2019.02.003</pub-id>
<pub-id pub-id-type="pmid">30771710</pub-id>
</element-citation>
</ref>
<ref id="B184-life-10-00082">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aydemir</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Deveci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Taskin</surname>
<given-names>O.E.</given-names>
</name>
<name>
<surname>Taneli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Esen-Danaci</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Serum brain-derived neurotrophic factor level in dysthymia: A comparative study with major depressive disorder</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2007</year>
<volume>31</volume>
<fpage>1023</fpage>
<lpage>1026</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.02.013</pub-id>
<pub-id pub-id-type="pmid">17433517</pub-id>
</element-citation>
</ref>
<ref id="B185-life-10-00082">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molendijk</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Spinhoven</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Polak</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bus</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Penninx</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Elzinga</surname>
<given-names>B.M.</given-names>
</name>
</person-group>
<article-title>Serum BDNF concentrations as peripheral manifestations of depression: Evidence from a systematic review and meta-analyses on 179 associations (N=9484)</article-title>
<source/>Mol. Psychiatry
          <year>2014</year>
<volume>19</volume>
<fpage>791</fpage>
<lpage>800</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2013.105</pub-id>
<pub-id pub-id-type="pmid">23958957</pub-id>
</element-citation>
</ref>
<ref id="B186-life-10-00082">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polyakova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stuke</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schuemberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schoenknecht</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schroeter</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>BDNF as a biomarker for successful treatment of mood disorders: A systematic &amp; quantitative meta-analysis</article-title>
<source/>J. Affect. Disord.
          <year>2015</year>
<volume>174</volume>
<fpage>432</fpage>
<lpage>440</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2014.11.044</pub-id>
<pub-id pub-id-type="pmid">25553404</pub-id>
</element-citation>
</ref>
<ref id="B187-life-10-00082">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Malberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D’Sa</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Neuronal plasticity and survival in mood disorders</article-title>
<source/>Biol. Psychiatry
          <year>2000</year>
<volume>48</volume>
<fpage>732</fpage>
<lpage>739</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(00)00935-5</pub-id>
<pub-id pub-id-type="pmid">11063970</pub-id>
</element-citation>
</ref>
<ref id="B188-life-10-00082">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McAllister</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Neurotrophins and synaptic plasticity</article-title>
<source/>Annu. Rev. Neurosci.
          <year>1999</year>
<volume>22</volume>
<fpage>295</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.22.1.295</pub-id>
<pub-id pub-id-type="pmid">10202541</pub-id>
</element-citation>
</ref>
<ref id="B189-life-10-00082">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenberg</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hempstead</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>New insights in the biology of bdnf synthesis and release: Implications in CNS function</article-title>
<source/>J. Neurosci.
          <year>2009</year>
<volume>29</volume>
<fpage>12764</fpage>
<lpage>12767</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3566-09.2009</pub-id>
<pub-id pub-id-type="pmid">19828787</pub-id>
</element-citation>
</ref>
<ref id="B190-life-10-00082">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stanek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gunstad</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leahey</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Glickman</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Spitznagel</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Juvancic Heltzel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Serum brain-derived neurotrophic factor is associated with reduced appetite in healthy older adults</article-title>
<source/>J. Nutr. Health Aging
          <year>2008</year>
<volume>12</volume>
<fpage>183</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1007/BF02982616</pub-id>
<pub-id pub-id-type="pmid">18309438</pub-id>
</element-citation>
</ref>
<ref id="B191-life-10-00082">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ikeda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yahata</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Nagano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Toyota</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Okubo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia</article-title>
<source/>Schizoph. Res.
          <year>2008</year>
<volume>101</volume>
<fpage>58</fpage>
<lpage>66</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2008.01.017</pub-id>
</element-citation>
</ref>
<ref id="B192-life-10-00082">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machado-Vieira</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Leke</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cereser</surname>
<given-names>V.H.</given-names>
</name>
<name>
<surname>Zanatto</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kapczinski</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>D.O.</given-names>
</name>
<name>
<surname>Portela</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Gentil</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode</article-title>
<source/>Biol. Psychiatry
          <year>2007</year>
<volume>61</volume>
<fpage>142</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2006.03.070</pub-id>
<pub-id pub-id-type="pmid">16893527</pub-id>
</element-citation>
</ref>
<ref id="B193-life-10-00082">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tsujii</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tsuchiya</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Sekine</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Minabe</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takei</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2006</year>
<volume>30</volume>
<fpage>1529</fpage>
<lpage>1531</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2006.06.018</pub-id>
<pub-id pub-id-type="pmid">16876305</pub-id>
</element-citation>
</ref>
<ref id="B194-life-10-00082">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakazato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kumakiri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Koizumi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mitsumori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Komatsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders</article-title>
<source/>Biol. Psychiatry
          <year>2003</year>
<volume>54</volume>
<fpage>485</fpage>
<lpage>490</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(02)01746-8</pub-id>
<pub-id pub-id-type="pmid">12915293</pub-id>
</element-citation>
</ref>
<ref id="B195-life-10-00082">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciammola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sassone</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cannella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calza</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poletti</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Frati</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Squitieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Silani</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington’s disease patients</article-title>
<source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
          <year>2007</year>
<volume>144</volume>
<fpage>574</fpage>
<lpage>577</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30501</pub-id>
</element-citation>
</ref>
<ref id="B196-life-10-00082">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazzichi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Da Valle</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giacomelli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sernissi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giannaccini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Betti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ciregia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giusti</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Scarpellini</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A multidisciplinary approach to study the effects of balneotherapy and mud-bath therapy treatments on fibromyalgia</article-title>
<source/>Clin. Exp. Rheumatol.
          <year>2013</year>
<volume>31</volume>
<fpage>S111</fpage>
<lpage>S120</lpage>
<pub-id pub-id-type="pmid">24373369</pub-id>
</element-citation>
</ref>
<ref id="B197-life-10-00082">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buselli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Veltri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baldanzi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bonotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chiumiento</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Girardi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guglielmi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dell’Osso</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Plasma brain-derived neurotrophic factor (BDNF) and serum cortisol levels in a sample of workers exposed to occupational stress and suffering from adjustment disorders</article-title>
<source/>Brain Behav.
          <year>2019</year>
<volume>9</volume>
<fpage>e01298</fpage>
<pub-id pub-id-type="doi">10.1002/brb3.1298</pub-id>
<pub-id pub-id-type="pmid">31197968</pub-id>
</element-citation>
</ref>
<ref id="B198-life-10-00082">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Portela</surname>
<given-names>L.V.</given-names>
</name>
<name>
<surname>Bohmer</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Oses</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Lara</surname>
<given-names>D.R.</given-names>
</name>
</person-group>
<article-title>Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia</article-title>
<source/>Neurochem. Res.
          <year>2010</year>
<volume>35</volume>
<fpage>830</fpage>
<lpage>834</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-010-0129-z</pub-id>
<pub-id pub-id-type="pmid">20119637</pub-id>
</element-citation>
</ref>
<ref id="B199-life-10-00082">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yasutake</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yanagawa</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoneda</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: Comparison between Alzheimer’s disease and vascular dementia</article-title>
<source/>Eur. Arch. Psychiatry Clin. Neurosci.
          <year>2006</year>
<volume>256</volume>
<fpage>402</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1007/s00406-006-0652-8</pub-id>
<pub-id pub-id-type="pmid">16783499</pub-id>
</element-citation>
</ref>
<ref id="B200-life-10-00082">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lommatzsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Niewerth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klotz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schulte-Herbruggen</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zingler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schuff-Werner</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Virchow</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Platelet and plasma BDNF in lower respiratory tract infections of the adult</article-title>
<source/>Respir. Med.
          <year>2007</year>
<volume>101</volume>
<fpage>1493</fpage>
<lpage>1499</lpage>
<pub-id pub-id-type="doi">10.1016/j.rmed.2007.01.003</pub-id>
<pub-id pub-id-type="pmid">17317133</pub-id>
</element-citation>
</ref>
<ref id="B201-life-10-00082">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.B.</given-names>
</name>
</person-group>
<article-title>The role of BDNF in the neuroimmune axis regulation of mood disorders</article-title>
<source/>Front. Neurol.
          <year>2019</year>
<volume>10</volume>
<fpage>515</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2019.00515</pub-id>
<pub-id pub-id-type="pmid">31231295</pub-id>
</element-citation>
</ref>
<ref id="B202-life-10-00082">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pariante</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2017</year>
<volume>27</volume>
<fpage>554</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2017.04.001</pub-id>
<pub-id pub-id-type="pmid">28479211</pub-id>
</element-citation>
</ref>
<ref id="B203-life-10-00082">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wohleb</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Integrating neuroimmune systems in the neurobiology of depression</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2016</year>
<volume>17</volume>
<fpage>497</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1038/nrn.2016.69</pub-id>
<pub-id pub-id-type="pmid">27277867</pub-id>
</element-citation>
</ref>
<ref id="B204-life-10-00082">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayley</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Poulter</surname>
<given-names>M.O.</given-names>
</name>
<name>
<surname>Merali</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Anisman</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity</article-title>
<source/>Neuroscience
          <year>2005</year>
<volume>135</volume>
<fpage>659</fpage>
<lpage>678</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.03.051</pub-id>
<pub-id pub-id-type="pmid">16154288</pub-id>
</element-citation>
</ref>
<ref id="B205-life-10-00082">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koo</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Ferguson</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2010</year>
<volume>107</volume>
<fpage>2669</fpage>
<lpage>2674</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0910658107</pub-id>
<pub-id pub-id-type="pmid">20133768</pub-id>
</element-citation>
</ref>
<ref id="B206-life-10-00082">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kauppi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Persson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nyberg</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Additive genetic effect of APOE and BDNF on hippocampus activity</article-title>
<source/>Neuroimage
          <year>2014</year>
<volume>89</volume>
<fpage>306</fpage>
<lpage>313</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.11.049</pub-id>
<pub-id pub-id-type="pmid">24321557</pub-id>
</element-citation>
</ref>
<ref id="B207-life-10-00082">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Leime</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Cryan</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Nolan</surname>
<given-names>Y.M.</given-names>
</name>
</person-group>
<article-title>Nuclear deterrents: Intrinsic regulators of IL-1beta-induced effects on hippocampal neurogenesis</article-title>
<source/>Brain Behav. Immun.
          <year>2017</year>
<volume>66</volume>
<fpage>394</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2017.07.153</pub-id>
<pub-id pub-id-type="pmid">28751020</pub-id>
</element-citation>
</ref>
<ref id="B208-life-10-00082">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calabrese</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Racagni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gass</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Riva</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Molteni</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor: A bridge between inflammation and neuroplasticity</article-title>
<source/>Front. Cell. Neurosci.
          <year>2014</year>
<volume>8</volume>
<fpage>430</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2014.00430</pub-id>
<pub-id pub-id-type="pmid">25565964</pub-id>
</element-citation>
</ref>
<ref id="B209-life-10-00082">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirayama</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2015</year>
<volume>25</volume>
<fpage>2449</fpage>
<lpage>2458</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.09.002</pub-id>
<pub-id pub-id-type="pmid">26419294</pub-id>
</element-citation>
</ref>
<ref id="B210-life-10-00082">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibney</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>McGuinness</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prendergast</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Harkin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>T.J.</given-names>
</name>
</person-group>
<article-title>Poly I: C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression</article-title>
<source/>Brain Behav. Immun.
          <year>2013</year>
<volume>28</volume>
<fpage>170</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbi.2012.11.010</pub-id>
<pub-id pub-id-type="pmid">23201589</pub-id>
</element-citation>
</ref>
<ref id="B211-life-10-00082">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrientos</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Sprunger</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Campeau</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>L.R.</given-names>
</name>
<name>
<surname>Rudy</surname>
<given-names>J.W.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1beta administration</article-title>
<source/>J. Neuroimmunol.
          <year>2004</year>
<volume>155</volume>
<fpage>119</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/j.jneuroim.2004.06.009</pub-id>
<pub-id pub-id-type="pmid">15342202</pub-id>
</element-citation>
</ref>
<ref id="B212-life-10-00082">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lotrich</surname>
<given-names>F.E.</given-names>
</name>
<name>
<surname>Albusaysi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ferrell</surname>
<given-names>R.E.</given-names>
</name>
</person-group>
<article-title>Brain-derived neurotrophic factor serum levels and genotype: Association with depression during interferon-alpha treatment</article-title>
<source/>Neuropsychopharmacology
          <year>2013</year>
<volume>38</volume>
<fpage>985</fpage>
<lpage>995</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.263</pub-id>
<pub-id pub-id-type="pmid">23303061</pub-id>
</element-citation>
</ref>
<ref id="B213-life-10-00082">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kenis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Prickaerts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>van Os</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Koek</surname>
<given-names>G.H.</given-names>
</name>
<name>
<surname>Robaeys</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Steinbusch</surname>
<given-names>H.W.</given-names>
</name>
<name>
<surname>Wichers</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Depressive symptoms following interferon-alpha therapy: Mediated by immune-induced reductions in brain-derived neurotrophic factor?</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2011</year>
<volume>14</volume>
<fpage>247</fpage>
<lpage>253</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145710000830</pub-id>
<pub-id pub-id-type="pmid">20667172</pub-id>
</element-citation>
</ref>
<ref id="B214-life-10-00082">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortese</surname>
<given-names>G.P.</given-names>
</name>
<name>
<surname>Barrientos</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Maier</surname>
<given-names>S.F.</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes</article-title>
<source/>J. Neurosci.
          <year>2011</year>
<volume>31</volume>
<fpage>4274</fpage>
<lpage>4279</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5818-10.2011</pub-id>
<pub-id pub-id-type="pmid">21411668</pub-id>
</element-citation>
</ref>
<ref id="B215-life-10-00082">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Balazs</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Soiampornkul</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Thangnipon</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cotman</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction</article-title>
<source/>Neurobiol. Aging
          <year>2008</year>
<volume>29</volume>
<fpage>1380</fpage>
<lpage>1393</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2007.02.027</pub-id>
<pub-id pub-id-type="pmid">17467122</pub-id>
</element-citation>
</ref>
<ref id="B216-life-10-00082">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlos</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Cotman</surname>
<given-names>C.W.</given-names>
</name>
</person-group>
<article-title>IL-1β impairs retrograde flow of BDNF signaling by attenuating endosome trafficking</article-title>
<source/>J. Neuroinflamm.
          <year>2017</year>
<volume>14</volume>
<fpage>29</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-017-0803-z</pub-id>
<pub-id pub-id-type="pmid">28153028</pub-id>
</element-citation>
</ref>
<ref id="B217-life-10-00082">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>MicroRNA-211/BDNF axis regulates LPS-induced proliferation of normal human astrocyte through PI3K/AKT pathway</article-title>
<source/>Biosci. Rep.
          <year>2017</year>
<volume>37</volume>
<pub-id pub-id-type="doi">10.1042/BSR20170755</pub-id>
<pub-id pub-id-type="pmid">28790168</pub-id>
</element-citation>
</ref>
<ref id="B218-life-10-00082">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>MiR-140/BDNF axis regulates normal human astrocyte proliferation and LPS-induced IL-6 and TNF-alpha secretion</article-title>
<source/>Biomed. Pharmacother.
          <year>2017</year>
<volume>91</volume>
<fpage>899</fpage>
<lpage>905</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2017.05.016</pub-id>
<pub-id pub-id-type="pmid">28501777</pub-id>
</element-citation>
</ref>
<ref id="B219-life-10-00082">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.K.</given-names>
</name>
</person-group>
<article-title>Decreased plasma BDNF level in depressive patients</article-title>
<source/>J. Affect. Disord.
          <year>2007</year>
<volume>101</volume>
<fpage>239</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2006.11.005</pub-id>
<pub-id pub-id-type="pmid">17173978</pub-id>
</element-citation>
</ref>
<ref id="B220-life-10-00082">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendlewicz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kriwin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Oswald</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Souery</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alboni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Brunello</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study</article-title>
<source/>Int. Clin. Psychopharmacol.
          <year>2006</year>
<volume>21</volume>
<fpage>227</fpage>
<lpage>231</lpage>
<pub-id pub-id-type="doi">10.1097/00004850-200607000-00005</pub-id>
<pub-id pub-id-type="pmid">16687994</pub-id>
</element-citation>
</ref>
<ref id="B221-life-10-00082">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savitz</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Teague</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Misaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Macaluso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wurfel</surname>
<given-names>B.E.</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Drevets</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gleason</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Drevets</surname>
<given-names>W.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2x2 double-blind, randomized, placebo-controlled, phase IIA clinical trial</article-title>
<source/>Transl. Psychiatry
          <year>2018</year>
<volume>8</volume>
<fpage>27</fpage>
<pub-id pub-id-type="doi">10.1038/s41398-017-0073-7</pub-id>
<pub-id pub-id-type="pmid">29362444</pub-id>
</element-citation>
</ref>
<ref id="B222-life-10-00082">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazza</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Lucchi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tringali</surname>
<given-names>A.G.M.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Botti</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Clerici</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2018</year>
<volume>84</volume>
<fpage>229</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2018.03.012</pub-id>
<pub-id pub-id-type="pmid">29535038</pub-id>
</element-citation>
</ref>
<ref id="B223-life-10-00082">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowland</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>B.I.</given-names>
</name>
<name>
<surname>Upthegrove</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chatterjee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gallacher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Marwaha</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: Systematic review and meta-analyses</article-title>
<source/>Br. J. Psychiatry
          <year>2018</year>
<volume>213</volume>
<fpage>514</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.2018.144</pub-id>
<pub-id pub-id-type="pmid">30113291</pub-id>
</element-citation>
</ref>
<ref id="B224-life-10-00082">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Prvulovic</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Novel biomarkers in major depression</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2013</year>
<volume>26</volume>
<fpage>47</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0b013e32835a5947</pub-id>
<pub-id pub-id-type="pmid">23154643</pub-id>
</element-citation>
</ref>
<ref id="B225-life-10-00082">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hahn</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Marquand</surname>
<given-names>A.F.</given-names>
</name>
<name>
<surname>Ehlis</surname>
<given-names>A.-C.</given-names>
</name>
<name>
<surname>Dresler</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kittel-Schneider</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jarczok</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Lesch</surname>
<given-names>K.-P.</given-names>
</name>
<name>
<surname>Jakob</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Mourao-Miranda</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brammer</surname>
<given-names>M.J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Integrating Neurobiological Markers of Depression</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2011</year>
<volume>68</volume>
<fpage>361</fpage>
<lpage>368</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.178</pub-id>
<pub-id pub-id-type="pmid">21135315</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="life-10-00082-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Article Selection Flow Chart.</p>
</caption>
<graphic xlink:href="life-10-00082-g001"></graphic>
</fig>
<fig id="life-10-00082-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Complex interactions amongst hypothalamus-pituitary-adrenal axis (HPA-axis), neurotransmitters, and immune system. ACTH: adrenocorticotropic hormone; CRF: corticotrophin releasing factor; NE: norepinephrine; 5-HT: serotonin.</p>
</caption>
<graphic xlink:href="life-10-00082-g002"></graphic>
</fig>
<fig id="life-10-00082-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Cascade effects of pro-inflammatory cytokines on microglia and related functional changes. O<sub>2</sub>: oxygen; N nitrogen; CK: cytokines; TNF: tumor necrosis factor; IL: interleukin; BDNF: brain-derived neurotrophic factor.</p>
</caption>
<graphic xlink:href="life-10-00082-g003"></graphic>
</fig>
<fig id="life-10-00082-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Effects of pro-inflammatory cytokines on 5-HT metabolism, HPA-axis, and oxidative mechanisms. IFN: interferon; CRH: corticotropin-releasing hormone; PGE2: Prostaglandin E<sub>2</sub>; IDO indoleamine 2,3 dioxygenase; NO: nitric oxide.</p>
</caption>
<graphic xlink:href="life-10-00082-g004"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>